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Abstract 
Human induced pluripotent stem cells (iPS cells) resemble embryonic stem cells (ES 
cells) and can differentiate into all tissue types of our body. Hence human iPS cells 
serve as suitable candidates for disease modeling, drug development and cellular 
therapy. However, the differentiation efficiency of human iPS cells towards specific 
lineages is rather poor - particularly towards mesodermal and endodermal lineages, 
such as hematopoietic cells, hepatocytes and pancreatic cells. In this study, we aim to 
search for new approaches, which could enhance the differentiation efficiency of 
human iPS cells. 
 
Cell fusion exists physiologically in our body (e.g. muscle and liver cells), to make 
cells acquire increasing cellular function. In vitro, upon fusion of somatic cells with 
pluripotent stem cells, the somatic genome is reprogrammed into a pluripotent state. 
Hence, cell fusion is often used as a tool for studying reprogramming. We hypothesize 
that the somatic genome in such hybrids might contribute to their differentiation 
potential and thus enhances pluripotent stem cell differentiation. Therefore, we fused 
human iPS cells with hematopoietic stem cells (HSC) from cord blood to generate 
iPS/somatic cell hybrids, referred to as iPS hybrids. Shortly after fusion, iPS hybrids 
acquired similar characteristics as parental iPS cells, including gene expression 
profiles and epigenetic signatures. Different from parental iPS cells, iPS hybrids 
showed a prominent differentiation bias towards hematopoietic lineages but also 
towards other mesendodermal lineages. Interestingly, we found that the strong 
mesendodermal differentiation bias of iPS hybrids was already initiated at the 
primitive streak stage, when the first decision of mesendoderm or ectoderm 
specification is made. The prominent primitive streak development in iPS hybrids was 
directed by NODAL signaling. Accordingly, inhibition of NODAL signaling blunted 
the mesendodermal differentiation bias. 
 
Biomaterials can mimic properties of in vivo extracellular matrix (ECM) components 
and provide an in vitro cellular “niche”. Therefore biomaterials are expected to direct 
differentiation of pluripotent stem cells towards specific lineages. Similarly, small 
molecules activate or inhibit specific signaling pathways, which are crucial for cell 
fate specification and can affect differentiation capacity of pluripotent stem cells. To 
this end, we investigated whether the biomaterial Poly(L-lactide-co-D,L-lactide) 
(LR704) and the compound 1-ethyl-2-benzimidazolinone (EBIO), an activator of 
Ca2+-activated potassium channels (SKCas), affect human iPS cell differentiation. We 
found that both of LR704 and EBIO showed rather unspecific effects on the 
differentiation of human iPS cells. 
 
Thus, in the context studied here cell fusion of iPS cells with somatic cells is superior 
to biomaterials and small molecules in enhancing iPS cell differentiation. Taken 
together, we propose that cell fusion of iPS cells with somatic cells provides an 
efficient strategy for enhancing iPS cell differentiation towards cell types, which are 
notoriously difficult to obtain. 
  
	  	  	   II	  
Zusammenfassung 
Humane induzierte pluripotente Stammzellen (iPS Zellen) haben ähnliche 
Eigenschaften wie embryonale Stammzellen (ES Zellen) und können in alle Zellen 
unseres Körpers differenzieren. Daher bieten iPS Zellen geeignete Systeme für die 
Krankheitsmodellierung, die Arzneimittelentwicklung und die Zelltherapie. Alle 
potentiellen Anwendungen von iPS Zellen hängen von ihrer Differenziationsfähigkeit 
in vitro ab. Vielfach ist die Effizienz der iPS Zelldifferenzieung sehr begrenzt, 
besonders bei der Differenzierung in Zellen des Mesoderms und Endoderms, wie zum 
Beispiel in hämatopoetische Zellen, Leber-und Pankreaszellen. Ziel der vorliegenden 
Dissertation ist die Etablierung von Systemen, die die Differenzierungseffizienz von 
humanen iPS Zellen verbessern. Dazu wurden verschiedene Ansätze gewählt: 
Zellfusion, Biomaterialien und kleine pharmakologisch aktive Substanzen (small 
molecules). 
 
Die Zellfusion ist ein physiologisches Phänomen in unserem Körper, wie z. B. bei 
Muskelzellen und Leberzellen, um zelluläre Funktionen zu verstärken. In vitro wird 
durch die Fusion einer somatischen Zelle mit einer pluripotenten Stammzelle die 
somatische Zelle in einen pluripotenten Zustand reprogrammiert. Daher wird die 
Zellfusion als ein Weg zur Reprogrammierung somatischer Zellen benutzt. Bisher ist 
allerdings unbekannt,  wie sich die Fusion einer somatischen Zelle mit einer 
pluripotenten Zelle auf das Differenzierungspotential der pluripotenten Zelle auswirkt. 
Dieser Dissertation liegt die Hypothese zugrunde, dass durch Fusion einer 
somatischen Zelle mit einer iPS Zelle das Differenzierungspotential der iPS Zelle 
verstärkt werden kann.   
 
In vorausgegangenen Studien wurde gefunden, dass das Biomaterial Poly(L-lactid-co-
D,L-lactid) (LR704)  und die Substanz 1-ethyl-2-benzimidazolinone (EBIO), ein 
Aktivator der Ca2+-aktivierten Kaliumkanäle (Ca2+-activated potassium channels 
(SKCas), einen positiven Einfluss auf Maus ES Zellen haben und ihre Differenzierung 
in Herzmuskelzellen beschleunigt und verstärkt. Jedoch ist unbekannt, ob dies auch in 
gleicher Weise für humane iPS Zellen zutrifft.  
 
Es wurden daher humane iPS Zellen mit hämatopoetischen Stammzellen 
(hematopoietic stem cells, HSC) aus dem Nabelschnurblut fusioniert, um pluripotente 
iPS/HSC Hybride herzustellen. Das Differenzierungspotential der pluripotenten 
Hybride wurde analysiert. Parallel dazu wurde der Einfluss des Biomaterials LR704 
und der Substanz EBIO auf die Herzmuskelzelldifferenzierung von humanen iPS 
Zellen untersucht. 
 
Es wurde gefunden, dass iPS Zellhybride eine bevorzugte Differenzierung in Zellen 
des Mesendoderms zeigen. Diese Differenzierungsneigung zum Mesendoderm war 
abhängig vom Nodal Signaltransduktionsweg und Blockierung des Nodal 
Signalweges führte zum Verlust dieser mesendodermale Differenzierungsneigung. Der 
Einfluss des Biomaterials LR704 und der Substanz EBIO auf die Differenzierung von 
humanen iPS Zellen war im Wesentlichen unspezifisch und führte nicht zu einer 
Erhöhung der Herzmuskelzelldifferenzierung. 
 
Zusammenfassend ist festzustellen, dass die Fusion von iPS Zellen mit somatischen 
Zellen ein effizienter Weg ist, das Differenzierungspotential von iPS Zellen zu 
erhöhen. Dieses Ergebnis ist besonders wichtig, um Zelltypen zu erhalten, deren 
Differenzierung aus iPS Zellen bisher besonders schwierig ist. 
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Abbreviations 
Symbols Description 
AFP Alpha-fetoprotein 
ALB Albumin 
C-MYC V-myc avian myelocytomatosis viral oncogene homolog 
CD31/PECAM1 Platelet/endothelial cell adhesion molecule 1 
CD34 CD34 molecule 
CD45/PTPRC Protein tyrosine phosphatase, receptor type, C 
CDX2 Caudal type homeobox 2 
CK7/KRT7 Keratin 7 
CYP7A1 Cytochrome P450, family 7, subfamily A, polypeptide 1 
EOMES Eomesodermin 
FOXA2 Forkhead box A2 
GATA1 GATA binding protein 1 
GATA2 GATA binding protein 2 
GFAP Glial fibrillary acidic protein 
GSC Goosecoid homeobox 
HCN4 Hyperpolarization activated cyclic nucleotide-gated potassium 
channel 4 
KLF4 Kruppel-Like Factor 4 
MAP2 Microtubule-associated protein 2 
MIXL1 Mix paired-like homeobox 
NANOG Nanog homeobox 
NEUROG 3 Neurogenin 3 
NF Neurofilament 
NODAL Nodal growth differentiation factor 
OCT4 POU Class 5 Homeobox 1 
OLIG1 Oligodendrocyte transcription factor 1 
OSR1 Odd-skipped related 1 
PAX6 Paired box 6 
PDX1 Pancreatic and duodenal homeobox 1 
PU.1/SPI1 Spleen focus forming virus (SFFV) proviral integration 
oncogene spi1 
REX1 ZFP42 zinc finger protein 
RUNX1 Runt-related transcription factor 1 
SCL/TAL1 T-cell acute lymphocytic leukemia 1 
SOX1 SRY(Sex Determining Region Y)-Box1 
SOX17 SRY(Sex Determining Region Y)-Box17 
SOX2 SRY (Sex Determining Region Y)-Box 2 
T Brachyury homolog 
WT1 Wilms tumor 1 
α-MHC /MYH6 Myosin, heavy chain 6, cardiac muscle, alpha 
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1 Introduction 
1.1 Pluripotency and Reprogramming  
1.1.1 Pluripotency 
 
Stem cells are characterized as two distinct traits: self-renewal (unlimited proliferation 
capacity) and differentiation capacity (ability to generate mature cells) (Stadtfeld and 
Hochedlinger, 2010) (Fig. 1.1A).  According to different differentiation capacity, stem 
cells can be further defined as totipotent stem cells, pluripotent stem cells, multipotent 
stem cells and unipotent stem cells (Mitalipov and Wolf, 2009) (Fig. 1.1B). Totipotent 
stem cells, which can give rise to the entire embryo and supportive tissues, are 
referred to cells before morula stage of development (Condic, 2014; Mitalipov and 
Wolf, 2009). Cells after morula stage can only generate the three germ layers of the 
embryo (ectoderm, mesoderm and endoderm), called pluripotent stem cells, such as 
cells within inner cell mass (ICM) at blastocyst stage (Condic, 2014; Mitalipov and 
Wolf, 2009). Multipotent stem cells can differentiate into certain cell types, such as 
hematopoietic stem cells and neural stem cells. Unipotent stem cells can only generate 
one specific cell type, for instance epithelial stem cells.  
 
Fig. 1.1 Biology of stem cells. (A) Self-renewal and differentiation capacity of stem cells. (B) 
Early development of embryo (totipotent and pluripotent stem cells). 
 
1.1.1.1 Embryonic stem cells 
 
Embryonic stem cells (ES cells), which can be derived and stably maintained in in 
vitro culture, are pluripotent stem cells. Importantly, they have differentiation capacity 
towards three germ layers. The isolation of mouse ES cells from the ICM in pre-
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implantation mouse blastocyst was first reported in 1981 (Evans and Kaufman, 1981; 
Martin, 1981). In 1998, human ES cells were successfully isolated by Thomson and 
his colleagues (Thomson et al., 1998). The derivation of ES cells opens a new era to 
development study, drug discovery and regenerative medicine (Fig. 1.2).  
 
Fig. 1.2 Embryonic developmental process and derivation of ES cells (modified from 
NIH report 2001). During development, zygote forms blastocyst, containing inner cell mass 
(ICM), trophecotoderm and blastocyst cavity. ES cells are derived from the ICM. Later, three 
germ layers are generated through a process called gastrulation. Three germ layers include 
ectoderm, mesoderm and endoderm. Specifically, progenies of ectoderm refer to cells of 
neuroectoderm (neurons, astrocytes and oligodendrocytes) and surface ectoderm. Mesodermal 
cells include blood cells, mesenchymal stromal cells, muscle cells, kidney and reproductive 
system. Endodermal cells are hepatocytes, pancreatic cells, lung and thymus. 
 
Both mouse and human ES cells are maintained on mitotically inactivated mouse 
embryonic feeder cells (MEF), but they have different biological characters. Mouse 
ES cells have dome-like structure and respond to leukemia inhibitory factor (LIF), 
while human ES cells have cobblestone-like morphology and depend on basic 
fibroblast growth factor (bFGF). Further studies indicated that mouse epiblast cells, 
which are derived from post-implantation embryonic tissue, are very similar as human 
ES cells. They share culture morphology (Fig. 1.3), pluripotency signaling pathways 
(NODAL and FGF) and differentiation capacity towards three germ layers (Brons et 
al., 2007; Tesar et al., 2007). It is a widely accepted concept that human ES cells are 
primed pluripotent stem cells, whereas mouse ES cells are naive pluripotent stem cells 
(Tesar et al., 2007). Such difference might be due to the species difference. 
Embryonic diapause or delayed implantation exists in mouse blastocysts but is absent 
in human (Brons et al., 2007; Renfree and Shaw, 2000; Sui et al., 2013a).  
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Fig. 1.3 Growth morphology of mouse ES, mouse epiblast (EpiSC) and human ES cells 
(Tesar et al., 2007). Mouse ES cells grow in dome-like colonies. Mouse epiblast cells and 
human ES cells grow in flat and cobblestone-like colonies. 
 
1.1.1.2 Criteria to define pluripotency 
 
There are several criteria to define pluripotency of stem cells, including growth 
morphology, pluripotency marker expression, in vitro differentiation assay, teratoma 
assay, chimera assay and tetraploid complementation assay. 
 
Growth morphology. Mouse ES cells grow in dome-like compact colonies and 
respond to LIF, while human ES cells have cobblestone-like morphology and depend 
on bFGF (Brons et al., 2007; Tesar et al., 2007). 
 
Pluripotency marker expression. There is a set of pluripotency marker epression in 
pluripotent stem cells. Mouse and human ES cells share some of the pluripotency 
markers, such as OCT4, SOX2 and NANOG, but they also express different 
pluripotency markers (Pera et al., 2000). Mouse ES cells express stage specific 
embryonic antigen 1 (SSEA1), whereas human ES cells express tumor rejection 
antigens 1-60 (TRA-1-60), TRA-1-81 and SSEA3/4 (Table 1.1).  
 
Table 1.1 Marker expression and growth properties of mouse and human ES cells. 
Surface markers Mouse ES cells Human ES cells 
SSEA1 + - 
SSEA3/4 - + 
TRA-1-60/81 - + 
OCT4 + + 
SOX2 + + 
NANOG + + 
REX1 + - 
 
In vitro differentiation assay. ES cells start differentiation spontaneously, when 
growth factor, such as LIF or bFGF, is withdrawn from culture medium. When ES 
cells are differentiated in suspension culture condition, ES cells form embryoid bodies 
(EB), which mimic in vivo development and give rise to cell types of three germ 
layers (Keller, 2005) (Fig. 1.4).   
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Fig. 1.4 A model comparing the early stages of embryonic and ES/EB development 
(Keller, 2005). This indicates that EB development in vitro recapitulates developmental 
process in vivo. 
 
Teratoma assay. When pluripotent stem cells are injected into immune-compromised 
mice, they form teratoma, containing cell lineages of ectoderm, mesoderm and 
endoderm (Condic, 2014). Teratoma assay is commonly used for determining the in 
vivo three germ layer differentiation capacity of pluripotent stem cells. For mouse ES 
cells, teratoma is usually formed within 4 weeks; for human ES cells, it takes about 6-
8 weeks to form teratoma.  
 
Chimera assay. When pluripotent stem cells are injected into a developing blastocyst, 
they can develop together with the recipient pluripotent stem cells to form a chimeric 
embryo (Condic, 2014). Compared to teratoma assay, chimera formation is more 
stringent criteria for pluripotency, since pluripotent stem cells must generate 
functional progenies of different germ layers in order to contribute to the embryo. 
Frequently, germ line transmission of pluripotent stem cells is tested in this assay. 
When injected pluripotent stem cells develop into germ cells, they can generate 
subsequent offsprings.  
 
Tetraploid complementation assay. This is the golden standard for testing pluripotency 
(Jaenisch and Young, 2008). In tetraploid complementation assay, tetraploid cells 
were made from developing embryos at 2-cell stage by electronic current. When 
tetraploid cells develop to blastocyst, diploid pluripotent stem cells are injected into 
the blastocyst. In the following development, tetraploid cells give rise only to 
supporting tissues, whereas diploid pluripotent stem cells develop into tissue types, 
constituting the entire embryo (Yang et al., 2007). For ethical issues, human ES cells 
are not applied to both chimerism and tetraploid complementation assay. Human ES 
cells resemble mouse epiblast cells, which are primed pluripotent stem cells. Mouse 
epiblast cells lose the ability to generate chimera and embryo in tetraploid 
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complementation assay (Jaenisch and Young, 2008). Therefore, it is likely that human 
ES cells would not form chimera or embryo in tetraploid complementation assay.  
 
1.1.2 Reprogramming 
 
Reprogramming is a process of erasing cell identity and dedifferentiating of a mature 
cell type into a naive state. There are several approaches to reprogram somatic cells 
into a pluripotent state, including somatic cell nuclear transfer (SCNT), cell fusion 
and iPS technology (Jaenisch and Young, 2008) (Fig. 1.5). 
 
Fig. 1.5 Strategies to induce pluripotency in somatic cells (Jaenisch and Young, 2008). By 
injecting somatic nucleus into an enucleated oocyte, somatic cells can be reprogrammed into 
a pluripotent state. However, such approach is inefficient and normally leads to serious 
abnormalities in offsprings due to faulty reprogramming. By fusing somatic cells with 
pluripotent stem cells, somatic genome is reprogrammed. Such reprogramming process is 
efficient but the fused cells contain double amount of DNA. When germ cells are put in 
prolonged in vitro culture, they are able to acquired pluripotency. However, such phenomenon 
has not yet been found in other somatic cells. In addition, reprogramming can also ben made 
through introducing defined factors (OCT4, SOX2, KLF4 and c-MYC) into somatic cells. 
 
1.1.2.1 Cell fusion 
 
Cell fusion exists as physiological and pathological phenomena in animal and human 
body. Muscle cells and hepatocytes fuse together as multinucleate or polyploid cells, 
to augment cell functions, such as increased contractile ability or metabolic output 
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(Guidotti et al., 2003; Kaufmann et al., 1999; Sullivan and Eggan, 2006). Cell fusion 
between tumor cells and other cells (e.g. connective tissue cells) was recently found to 
be a metastasis mechanism, enduing tumor cells with the ability to migrate into other 
tissues (Lu and Kang, 2009). 
 
As a research tool, cell fusion was used to generate specific antibodies, in which B 
cells were fused with tumor cells (Blann, 1979). Cell fusion between different cell 
types was also used to define tissue specific transcriptional activators or repressors of 
different cell types (Davidson, 1974; Looney et al., 2014). Interestingly, when somatic 
cells are fused with pluripotent stem cells, the somatic genome is reprogrammed into 
a pluripotent state (Do and Scholer, 2006; Foshay et al., 2012). Such an approach 
contributes to mechanismic studies of reprogramming.  
 
Specifically, in fusion between somatic and pluripotent stem cells, hybrids show 
growth morphology similar as the parental pluripotent stem cells, with similar 
doubling time (Han et al., 2008). They express pluripotency markers, down regulate 
tissue specific markers of parental somatic cells, reactivate inactive X chromosome of 
female somatic cells and show undifferentiated epigenetic landscape (Matveeva et al., 
1998; Tada et al., 2001). Gene expression pattern in hybrids reaches stability 3 days 
after cell fusion (Lee et al., 2009). They can differentiate into three germ layers both 
in vitro and in vivo (Pralong et al., 2005; Tat et al., 2011). When injected to diploid 
blastocyste, hybrids can generate chimeric embryos, contributing to all the three germ 
layers and extraembryonic tissues (Do et al., 2011; Pralong et al., 2005; Tada et al., 
2001). Compared to other methods, cell fusion provides a faster reprogramming 
approach with higher efficiency (Hasegawa et al., 2010).  
 
Pluripotent stem cells can reprogram the somatic fusion partner in cell fusion, 
whereas effects of somatic cells on differentiation capacity of pluripotent stem cells 
are hardly known. Given the existence of differentiation related factors (e.g. 
transcription factors and epigenetic marks around tissue specific genes) in the somatic 
cell, we expected that after cell fusion the somatic cell would enhance the 
differentiation capacity of the hybrids to some extent. One study based on cell fusion 
between myeloid cell and ES cell showed that the hybrids have similar differentiation 
capacity as parental ES cells to generate myeloid progeny (Yu et al., 2006). However, 
they used myeloid cells derived from in vitro differentiation of ES cells for fusion, 
instead of primary myeloid cells. They found the hybrids contained only 85 
chromosomes (7 chromosomes were lost), which might contribute to poor in vitro 
differentiation towards myeloid lineage afterwards. Therefore, the differentiation 
capacity of hybrids needs to be checked in hybrids from fusion of primary somatic 
cells and pluripotent stem cells with the complete set of chromosomes (92 
chromosomes).   
 
Another interesting observation, which encourages the investigation of the 
differentiation capacity of human hybrids, comes from the mouse study in our lab, 
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where mouse ES cell hybrids can revert to the 2n state (4n-2n transition, manuscript 
in preparation). Such finding makes the clinical application of hybrids feasible.  
 
Based on these previous findings, it is of interest to know whether in human cell 
fusion, the somatic cells would affect the differentiation capacity of pluripotent stem 
cells and whether a 4n-2n transition occurs in human hybrids. 
 
1.1.2.2 Induced pluripotent stem cells (iPS) technology 
 
Yamanaka et al. and others reported the success of generation mouse and human 
induced pluripotent stem cells (iPS cells), by introduction pluripotency transcription 
factors, such as OCT4, SOX2, KLF4 and c-MYC, into somatic cells (Eminli et al., 
2008; Kim et al., 2009b; Kim et al., 2008; Takahashi et al., 2007; Takahashi and 
Yamanaka, 2006). iPS cells, which contain the genetic information from the somatic 
cells, acquire similar characteristics as ES cells (Takahashi et al., 2007; Takahashi and 
Yamanaka, 2006) (Fig. 1.6). iPS cells express pluripotency markers, differentiate into 
progenies of three germ layers both in vitro and in vivo, form chimeric mice (Okita et 
al., 2007) and generate live mouse embryos in tetraploid complementation assay 
(Boland et al., 2009; Zhao et al., 2009). 
 
Fig. 1.6 Derivation of iPS cells (modified from NIH report 2001). Upon introducing 
defined transcriptional factors (e.g. OCT4, SOX2, KLF4 and c-MYC) into somatic cells, they 
can be reprogrammed into a pluripotent state, equivalent to ES cells. These cells are referred 
to as induced pluripotent stem cells (iPS cells). 
 
iPS technology circumvents the ethical difficulties with human ES cells and pushes 
forwards the applications of pluripotent stem cells, including disease modeling, drug 
screening and cellular transplantation (Yamanaka, 2009) (Fig. 1.7). 
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Fig. 1.7 Potential applications of iPS cells (Bellin et al., 2012). When iPS cells are derived 
from a patient, they carry specific disease identities. Therefore, the differentiated iPS cells can 
be used to mimic disease in vitro, to facilitate drug screening and toxicity test. Furthermore, 
they hold the promise to cure the disease via cellular transplantation.  
 
A tremendous rise of studies and publications came out within the last 7 years to 
characterize iPS cells, improve derivation approaches and prove the practical use of 
iPS cells (Cahan and Daley, 2013) (Fig. 1.8).   
 
 
Fig. 1.8 The rise of pluripotent stem cells in biomedical research (Cahan and Daley, 
2013). With the success of isolation ES cells and generation of iPS cells, more and more 
studies applied them as a research tool.  
 
There are two different approaches to generate iPS cells: integration and integration-
free methods (Bellin et al., 2012). Retrovirus (Takahashi et al., 2007; Takahashi and 
Yamanaka, 2006) and lentivirus (Park et al., 2008; Warlich et al., 2011) delivery 
methods are typical integration approaches. So far, these methods are applied by most 
studies due to the high efficiency of iPS generation compared to integration-free 
approaches (Bellin et al., 2012). However, for clinical application of iPS cells, 
integration-free methods, such as microRNA(Anokye-Danso et al., 2011; Miyoshi et 
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al., 2011) and protein (Kim et al., 2009a; Zhou et al., 2009), are more preferable for 
future studies. 
 
Studies of the reprogramming machinery during iPS generation revealed that it is a 
slow and complex process, involving presumably two phases (Muraro et al., 2013) 
(Fig. 1.9). In the early phase, reprogramming is initiated by the exogenous expression 
of OSKM factors, resulting in down-regulation of somatic lineage-specific genes. 
Enhanced cell proliferation and change of cell morphology are also observed in the 
early phase (Mikkelsen et al., 2008). The mesenchymal-to-epithelial transition (MET) 
occurs, which is characterized as down-regulation of mesenchymal gene expression 
and up-regulation of epithelial gene expression (Samavarchi-Tehrani et al., 2010). 
Epigenetically, histone modifications add transcriptional active marks to promoter or 
enhancer regions of pluripotency genes (Koche et al., 2011). Stable iPS colonies are 
formed from day 10 on, which have the morphology of pluripotent stem cells and can 
not reverse to somatic cells upon withdrawal of OSKM factors (Brambrink et al., 
2008; Stadtfeld et al., 2008). The occurrence of stable iPS cells marks the beginning 
of late phase of reprogramming.  
 
Fig. 1.9 Key molecule events during reprogramming (Muraro et al., 2013). 
Reprogramming of somatic cells into iPS cells involves many molecular events. Upon the 
introduction of pluripotentcy transcription factors to somatic cells, cell proliferation increases 
and mesenchymal-to-epithelial transition (MET) occurs. iPS colonies appear after around 10 
days. Pluripotency gene expression, such as NANOG and TRA-1-60, is up-regulated in iPS 
cells. Telomerase reverse transcriptase (Tert) and X chromosome (X chro.) in iPS cells are 
reactivated. Horizontal axis: days post introduction of reprogramming factors (OCT4, SOX2, 
KLF4 and c-MYC). 
 
In the late phase of reprogramming, epigenetic composition changes massively. 
Promoter regions of lineage-specific genes are covered by bivalent marks, which 
involve both transcriptional repressive and active marks (Bernstein et al., 2006; 
Hawkins et al., 2010; Mikkelsen et al., 2008; Mikkelsen et al., 2007). DNA 
demehylation is found in pluripotency genes (Maherali et al., 2007; Mikkelsen et al., 
2008). Accordingly, Nanog and Tra-1-60, which are considered as major pluripotency 
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markers, are expressed in iPS cells (Zhou et al., 2009). Elongation of telomere by 
activated telomerase reverse transcriptase (tert) and reactivation of X chromosome are 
found in late stage of reprogramming (Maherali et al., 2007; Marion et al., 2009; 
Stadtfeld et al., 2008; Tomoda et al., 2012).  
 
Since iPS cells carry the genetic information of the somatic cells, iPS cells derived 
from patient samples are used for disease modeling. Disease-specific iPS cells have 
been generated from different diseases, including neurological, hematological, 
metabolic, cardiovascular and primary immune-deficiency diseases (Bellin et al., 
2012; Robinton and Daley, 2012). However, not every disease-specific iPS cells can 
recapitulate the phenotype of the disease in the culture dish, which could be due to 
gene correction processes during reprogramming or unsuitable in vitro culture 
condition (Robinton and Daley, 2012) (Table 1.2). Thus, so far rather few disease-
specific iPS cells have contributed to drug development.  
 
Table 1.2 List of disease-specific iPS cells (Bellin et al., 2012; Robinton and Daley, 2012). 
Disease Symptoms Phenotype 
recapitulati
on 
References 
Neurological diseases 
Alzheimer’s 
disease 
Progressive memory 
disorientation, 
impaired cognition 
Yes (Israel et al., 
2012; Yagi et 
al., 2011) 
Amyotrophic 
lateral 
sclerosis 
(ALS) 
Progressive loss of 
motor neurons, 
neuromuscular 
degeneration 
No (Bilican et al., 
2012; Dimos et 
al., 2008) 
Parkinson’s 
disease 
Degeneration of 
neural system 
No (Hargus et al., 
2010; Soldner 
et al., 2009) 
Hematological diseases 
Fanconi 
anemia 
Abnormalities in 
multiple organs, e.g. 
bone marrow failure 
No (gene 
repair) 
(Raya et al., 
2009) 
β-thalassemia Reduced synthesis of 
β-hemoglobin and 
severe anemia 
No (Ye et al., 
2009) 
Cardiovascular diseases 
Type 1 and 2 
long QT 
syndromes 
Abnormality of 
depolarization of 
heart 
Yes (Itzhaki et al., 
2011; Moretti 
et al., 2010) 
 
As for applying iPS cells in cellular transplantation, there are also some challenges 
ahead, such as low efficiency of in vitro differentiation of iPS cells and safety issues 
(Robinton and Daley, 2012). Taken together, even though iPS cells hold enormous 
application potentials, efforts are still needed to circumvent the technical obstacles 
before their application in the clinics (e.g. drug or cellular therapy).  
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1.2 Differentiation 
 
Differentiation is the opposite process of reprogramming, turning cells from a 
pluripotent state into terminal differentiated state. Through the process of 
differentiation, pluripotent stem cells acquire cell identity of specific lineages. 
 
1.2.1 Development of three germ layers 
 
Starting from the zygote, differentiation capacity of cells gradually narrows down 
from totipotency to unipotency. After several rounds of cell division totipotent stem 
cells reach to morula stage and give rise to ICM or trophectoderm tissues (Yang et al., 
2007). Within the ICM, stem cells further differentiate into epiblast cells and 
extraembryonic endoderm. Epiblast cells would generate three germ layers as well as 
the germ cells; while extraembryonic endoderm develops into yolk sac, which 
together with the placenta derived from trophectoderm to support the growth of the 
embryo. Gastrulation is the process from epiblast cells to form the three germ layers 
(Mikawa et al., 2004). In mammals, the hallmark of gastrulation is the formation of 
primitive streak, a transient structure which is colonized by mesodermal and 
endodermal progenitors (mesendoderm) (Mikawa et al., 2004). Within the primitive 
streak, cells migrated from posterior epiblast undergo an epithelial to mesenchymal 
transition (EMT) to form definitive endoderm and mesoderm cell lineages (Brennan 
et al., 2001; Keller, 2005). The anterior epiblast then gives rise to neuroectoderm and 
surface ectoderm, guided by the interaction with adjacent extraembryonic endoderm 
(Lawson et al., 1991; Quinlan et al., 1995) (Fig. 1.10).  
 
Fig. 1.10 Model of early development of a zygote. A zygote (a fertilized egg) can develop 
through a stage wise process to form the entire organ (e.g. germ cells and progenies from 
ectoderm, mesoderm and endoderm) as well as the supporting tissues (e.g. yolk sac and 
placenta). ICM: inner cell mass. 
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Specifically, epiblast cells that move to the most anterior region of the primitive streak 
form definitive endoderm. Cells, which move to the more anterior position of the 
primitive streak, form cardiac mesoderm, head mesenchyme and paraxial mesoderm. 
Epiblast cells which migrate to the posterior part of the primitive streak give rise to 
hematopoietic and vascular cells (Tam and Behringer, 1997). Following gastrulation, 
mesendodermal cells move out of the primitive streak and further develop to 
respective cell types and organs.  
 
To define and target cells at different developmental stages, a panel of specific 
markers are applied (Table 1.3). 
Table 1.3 Tissue specific markers of distinct developmental stages. 
Developmental stages Markers 
ICM OCT4, NANOG, SOX2, FGF4 (Avilion et al., 
2003; Nichols et al., 1998; Pesce and Scholer, 
2000) 
Trophoectoderm BMP4, EOMES (Brennan et al., 2001), CDX2 
(Chawengsaksophak et al., 1997) 
Epiblast OCT4, NANOG, SOX2, TRA-1-60, SSEA4, 
FOXD3, EpCAM (Hanna et al., 2002; Mummery 
et al., 2012) 
Extraembryonic endoderm OTX2 (Brennan et al., 2001), GATA6 (Mesnard 
et al., 2006; Rossant et al., 2003), LEFTY1 
(Mesnard et al., 2006), DKK1 (Glinka et al., 
1998), CER1 (Belo et al., 1997) 
Primitive streak 
(mesendoderm) 
EOMES (Brennan et al., 2001), T, MIXL1 (Hart 
et al., 2002; Mummery et al., 2012), GSC (Blum 
et al., 1992)  
Germ cells OCT4 (Pesce and Scholer, 2000), STELLA 
(Saitou et al., 2002) 
Ectoderm SOX1, PAX6 (Koch et al., 2009) 
Mesoderm MESP1 (cardiac); FLK1 (hematopoietic) (Wu et 
al., 2008);  
Endoderm FOXA2, SOX17 (Weidgang et al., 2013) 
 
1.2.2 Signaling pathways involving in three germ layer development  
 
Signaling pathways, such as NODAL, wingless-type MMTV integration site family 
(WNT), bone morphogenetic protein (BMP) and fibroblast growth factor (FGF) 
signaling, are very important for cell fate determination (Murry and Keller, 2008; Tam 
and Loebel, 2007). 
 
NODAL signaling, which belongs to TGF-beta superfamily, plays an essential role in 
primitive streak formation (Conlon et al., 1994). This pathway is activated by binding 
of ligands (e.g. Activin and Nodal) to cell surface receptor (Activin receptor-like 
kinase) (Shi and Massague, 2003). Following ligand binding, the intracellular 
transducer SMAD2/3 gets phosphorylated and regulates target gene expression 
together with SMAD4 (Shi and Massague, 2003) (Fig. 1.11). Prior to the gastrulation, 
	  	  	   13	  
NODAL is required for establishing anterior-posterior polarity within the epiblast and 
the highest NODAL expression is in the posterior epiblast, which later forms the 
primitive streak (Brennan et al., 2001; Varlet et al., 1997). NODAL knockout embryos 
show developmental arrest before gastrulation and are devoid of primitive streak 
formation (Conlon et al., 1994). Some studies suggested that NODAL drives 
mesendodermal differentiation by actively up-regulating the expression of MIXL1 and 
GSC (Massague and Xi, 2012; Xi et al., 2011).  
 
Fig. 1.11 Schematic representation of NODAL signaling. When NODAL ligands bind to 
their receptors, SMAD2/3 gets phosphorylated and regulates the downstream gene expression 
together with SMAD4.  
 
WNT signaling is important for primitive streak formation and mesoderm 
differentiation (Liu et al., 1999). WNT signaling contains canonical (beta-catenin 
dependent) and non-canonical pathways (beta-catenin independent) (Knofler and 
Pollheimer, 2013). In canonical pathway, WNT ligands (e.g. WNT3) bind to receptors 
(Frizzled and low-density lipoprotein receptor protein 5/6), lead to the accumulation 
of beta-catenin and activate the transcription of target genes (e.g. C-MYC, T) (Kim et 
al., 2013; Reya and Clevers, 2005; Wray et al., 2010; Wu and Pan, 2010). In non-
canonical pathway, such as WNT/planar cell polarity (WNT/PCP) pathway and 
WNT/Ca2+ pathway, WNT ligands (WNT5A, WNT11) bind to Frizzled only and 
activate downstream signaling pathways to regulate cell movement and differentiation 
(e.g. HSC proliferation and differentiation) (Kim et al., 2013; Komiya and Habas, 
2008; Reya and Clevers, 2005) (Fig. 1.12). WNT3 expression is first detected just 
before gastrulation in mouse and is confined to the posterior epiblast (Liu et al., 
1999). During the gastrulation, WNT3 expression is restricted in the posterior and 
lateral regions of the primitive streak, regulating mesoderm differentiation (Gadue et 
al., 2006; Liu et al., 1999). Knockout of WNT3 results in the lack of primitive streak 
formation and mesoderm differentiation (Liu et al., 1999). 
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Fig. 1.12 Schematic representation of WNT signaling. In canonical pathway, WNT ligands 
bind to cellular receptors, leading to the accumulation of beta-catenin and the regulation of 
gene expression during gastrulation. In non-canonical pathway, WNT ligands only bind to 
Frizzled receptor. Through planar cell polarity (PCP) pathway, actin polymerization is 
activated following ligand binding (e.g. WNT5a and WNT11), which in turn regulates cell 
polarization and motility. WNT/Ca2+ non-canonical pathway depends on the release of Ca2+ 
from endoplasmic reticulum, which can activate Ca2+ sensitive downstream transcription 
factors (e.g. protein kinase C and nuclear factor kB) to regulate ventral cell fate (Komiya and 
Habas, 2008).  
 
BMP is also a member of TGF-beta superfamily. Different from NODAL, BMP 
activates activin receptor-like kinase receptor, phosphorylates SMAD1/5 and then co-
assists with SMAD4 to regulate target gene expression (Shi and Massague, 2003) 
(Fig. 1.13).  
 
Fig. 1.13 Schematic representation of BMP signaling. Following the binding of BMP 
ligands (e.g. BMP4) to cellular receptor, SMAD1/5 gets phosphorylated and in turn regulates 
mesoderm differentiation together with SMAD4.  
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BMP4 is first expressed in trophectoderm and during gastrulation it is expressed in 
posterior primitive streak and required for early mesoderm development (Fujiwara et 
al., 2002; Winnier et al., 1995). 
 
FGF signaling also participates in early differentiation, but its effect is not essential 
compared to other signalings. FGF is crucial for pluripotency maintenance of human 
ES cells via PI3K pathway (Feldman et al., 1995; Vallier et al., 2005). When human 
ES cells start the “default” differentiation towards neural lineages, FGF signaling 
drives the neural differentiation (Cohen et al., 2010). During gastrulation in mouse 
embryos, FGF signaling controls cell migration event in primitive streak (Sun et al., 
1999).  
 
Fig. 1.14 Regulation of signaling pathways during early development. During embryonic 
development, NODAL signaling is crucial for primitive streak formation and mesoderm and 
endoderm specification. WNT3 also participate in the regulation of primitive streak formation 
and mesoderm differentiation. BMP4 plays an important role in extraembryonic tissue 
formation and mesoderm differentiation. FGF signaling drives the ectoderm differentiation 
and assists mesodermal cell migration out from the primitive streak. 
 
So far, detailed pathway networks are still not fully understood. However, a crosstalk 
of different signaling pathways has been suggested by many studies (Brennan et al., 
2001; Hansson et al., 2009; Lindsley et al., 2006; Nostro et al., 2008). It is likely that 
germ layer specification is largely dependent on the temporal and spatial regulation of 
different signaling pathways, including NODAL, WNT3 and BMP4 (Gadue et al., 
2006; Nostro et al., 2008) (Fig. 1.14). 
 
1.2.3 In vitro differentiation methods of pluripotent stem cells 
 
iPS technology holds many application promises, all of which are heavily dependent 
on their in vitro differentiation ability and efficiency. However, except for the 
neuroectoderm differentiation – “default” pathway (Munoz-Sanjuan and Brivanlou, 
2002), in vitro differentiation of iPS cells remains challenging, in particular towards 
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most of the other cell types, such as definitive hematopoietic lineage and pancreatic 
cells (Robinton and Daley, 2012). What is more, due to the limited understanding of 
mammalian organ development, robust differentiation protocols of iPS cells are very 
rare (Feng et al., 2010; Mfopou et al., 2010; Narsinh et al., 2011; Robinton and Daley, 
2012; Zhang et al., 2009a). To improve the differentiation efficiency, many methods 
have been tested in the last decades, including EB assay, co-culture method, directed 
differentiation guided by defined factors, biomaterials and small molecules (Kardel 
and Eaves, 2012; Mummery et al., 2012).  
 
1.2.3.1 EB assay 
 
EB assay, which mimics the in vivo embryonic developmental process, is commonly 
used for differentiation of pluripotent stem cells. The EB size determines the 
differentiation kinetics in EB assay. Generally, small EB (150-300 µm; about 1000 
cells/EB) favor endothelial lineage and erythrocyte differentiation, and large EB (500-
1000 µm; about 2500-5000 cells/EB) give rise to more cardiomyocyte and hepatocyte 
lineages (Choi et al., 2010; Hwang et al., 2009; Ng et al., 2005). For mouse ES cell 
differentiation, homogeneous EB are generated by hanging drop method (Doetschman 
et al., 1985). In this method, a specific number of ES cells is put into one drop (30 
µL) on a cover slip. When the cover slip containing the cellular drops is inverted 
upside down, single cells aggregate to form three-dimensional EB by gravity.  
 
However, the hanging drop method is not applied for human pluripotent stem cells. 
Vast cell death occurs when cells are trypsinized into single cells (Kardel and Eaves, 
2012; Mummery et al., 2012). As a result, EB assay of human pluripotent stem cells is 
usually made from cell clumps by collagenase IV treatment. However, this makes it 
difficult to control the EB size and in turn affects the differentiation outcome. To 
overcome this problem and to generate homogeneous EB of human pluripotent stem 
cells, many modified EB assays have been developed, including spin EB and 
AggreWells (Stem Cell Technologies) (Mummery et al., 2012; Ng et al., 2005; Ungrin 
et al., 2008). Yet, by using these modified methods the differentiation efficiency of 
human stem cells is frequently rather poor compared to spontaneous differentiation.  
 
1.2.3.2 Co-culture differentiation 
 
Co-culture differentiation is characterized by applying stromal cells “feeder cells” to 
improve the differentiation efficiency of pluripotent stem cells towards specific 
lineages. OP9 cells, which are derived from osteopetrosis (op/op) mice (Kodama et 
al., 1994; Yoshida et al., 1990), are commonly used to generate hematopoietic cells 
(Choi et al., 2011; Vodyanik and Slukvin, 2007). For cardiomyocyte differentiation, 
END-2 cells, which are mouse visceral endoderm-like cells, are commonly used as 
stromal cells (Freund et al., 2010; Mummery et al., 2003; Mummery et al., 1991).  
 
Even though co-culture methods provide an easier and faster way to enhance the 
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differentiation of pluripotent stem cells, the disadvantages of this approach frequently 
prevent it from further application. For instance, the contamination of stromal cells 
within the differentiated cell population is inevitable. Besides, animal origin of these 
stromal cells causes problems, when differentiated cells from human pluripotent stem 
cells are considered for clinical application.  
 
1.2.3.3 Directed differentiation guided by defined factors 
 
Directed differentiation guided by defined factors is used by many research groups, 
and allows a controlled way to differentiate stem cells (Fig. 1.15).  
 
Fig. 1.15 Schematic representation of development pathway of hematopoietic 
differentiation in mouse and human (Kardel and Eaves, 2012). The hematopoietic 
developmental process is quite similar in both mouse and human, comprising three sequential 
developmental waves (mesoderm specification—primitive hematopoiesis—definitive 
hematopoiesis) guided by different sets of factors.  
 
Based on the knowledge of development biology, factors (e.g. signaling inhibitors or 
growth factors) are sequentially added to promote differentiation towards specific 
lineages. For the differentiation of hematopoietic stem cells from human pluripotent 
stem cells, BMP4, Activin (or NODAL inhibitor), bFGF and VEGF are used to induce 
primitive streak development and hematopoietic mesoderm commitment in the first 
phase (Kennedy et al., 2012). Then, hematopoietic cytokines (e.g. stem cell factor, IL-
6 and IGF-1) are added to promote the proliferation of hematopoietic stem cells 
(Kardel and Eaves, 2012; Kennedy et al., 2012). Further differentiation is induced by 
applying different cytokine cocktails, according to the cell types wanted. For example, 
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GM-CSF, IL-4 and TNF-α are added to the differentiation medium, in order to 
generate dendritic cells (DC) (Choi et al., 2011). Additionally, such directed 
differentiation approach can be applied in combination of the EB assay and/or 
biomaterials, to enhance differentiation efficiency.  
 
However, there are still some challenges ahead. The developmental processes of 
lineage specification from pluripotent stem cells are still largely unknown. Till now, 
only very limited cell types have been successfully and efficiently derived from 
pluripotent stem cells by using this method, such as endothelial cells and primitive 
hematopoietic stem cells. Moreover, different research groups use different cytokine 
cocktails, which makes it difficult to compare and judge the differentiation efficiency 
from different labs (Kardel and Eaves, 2012).   
 
1.2.3.4 Differentiation approach with biomaterials 
 
The extracellular matrix (ECM) is composed of different molecules, including 
glycosaminoglycans, proteoglycans, collagens and non-collagenous glyocoproteins 
(Rozario and DeSimone, 2010). Early from embryonic development, ECM is secreted 
by embryonic cells and functions as crucial element in cell proliferation, 
differentiation and morphogenesis (Rozario and DeSimone, 2010). The impact of 
ECM on cell biology lies in its components, which facilitate cell adherence and harbor 
signaling cues (i.e. growth factors) and thus regulate cell behaviors (i.e. growth and 
differentiation) (Dickinson et al., 2011; Purcell et al., 2012). The aim of biomaterial 
engineering is to generate artificial biomaterials, which facilitate cell growth or 
differentiation towards specific lineages, based on the knowledge of ECM and 
development biology.  
 
LR704, chemical name Poly(L-lactide-co-D,L-lactide), is composed of 70:30 molar 
ratio L-lactide : D, L-lactide (molecular formula: (C6H8O4)n). LR704 is a degradable 
polymers (half life: 290 days) and has a high biocompatibility and good mechanical 
property. Therefore it is frequently applied in orthopedic devices.  
 
Fig. 1.16 Cardiomyocyte differentiation of gPS cells on LR704 (day 8). gPS cells bear 
Oct4-GFP transgene. At day 8 of differentiation, a certain number of Oct4 positive cells were 
still observed under fluorescence microscope (right image). However, in such early 
differentiation time point, there were already lots of beating areas occurred in culture with 
LR704 (left image). Red circle: beating areas (Hoss et al., 2013). 
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Previous study by Hoß et al. showed that biomaterial LR704 promotes cardiomyocyte 
differentiation of mouse germline derived pluripotent stem cells (gPS cells)(Hoss et 
al., 2013). Compared to other biomaterials, such as Alginate and PVDF, 
cardiomyocyte differentiation of gPS cells on LR704 showed a faster kinetics and 
functional cardiomyocytes are generated (Fig. 1.16).  
 
Although LR704 can improve cardiomyocyte differentiation from mouse gPS cells, it 
is not clear whether this biomaterial would also enhance the cardiomyocyte 
differentiation of human iPS cells.  
 
1.2.3.5 Small molecule in differentiation assay 
 
Differentiation of pluripotent stem cells is guided by a series of signal pathways, 
which are activated or inhibited by small molecules (Schugar et al., 2008; Xu et al., 
2008). Small molecules have a rapid and reversible impact on differentiation (Li et al., 
2012). Similar to directed differentiation guided by defined factor, specific 
combinations of small molecules can be applied in the differentiation process 
according to the signal networks, which are targeted (Table 1.4).  
 
Table 1.4 List of small molecules in enhancing differentiation of pluripotent stem cells 
Cell types Small molecules Cell sources References 
Neural lineage Noggin+SB431542 Human ES cells (Chambers et al., 
2009) 
Definitive 
endoderm 
IDE1, IDE2, Im Mouse and human 
ES cells 
(Bone et al., 2011; 
Borowiak et al., 
2009) 
Pancreatic lineage Indolactam V Human ES cells (Chen et al., 2009) 
 
Ca2+-activated potassium channels (SKCas) include small (SK1, SK2 and SK3) and 
intermediate (SK4) forms are differentially distributed in different tissue types (Linta 
et al., 2013). Previous studies showed that SK3 activation is important for neural stem 
cell differentiation (Liebau et al., 2011; Liebau et al., 2007), and SK4 works as a 
strong regulator of pacemaker cell differentiation in mouse (Kleger et al., 2010). 1-
ethyl-2-benzimidazolinone (EBIO), which is the activator of SKCas, was used to 
enhance cardiac differentiation from mouse ES cells (Kleger et al., 2010) (Fig. 1.17). 
 
Fig. 1.17 Schematic representation (A) and RT-qPCR analysis (B) of EBIO experiments 
on mouse ES cells (Kleger et al., 2010). Mouse ES cells were differentiated by hanging drop 
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differentiation method and EBIO was added to culture for 10 days after plating EB into tissue 
culture plate. They showed that cardiomyocyte specific markers were up-regulated in EBIO 
treated cells.   
 
Given such promising effect of EBIO in enhancing cardiomyocyte differentiation in 
mouse ES cells, it is of interest to know its impact on cardiomyocyte differentiation in 
human pluripotent stem cells.   
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1.3 Aims and Objectives 
 
iPS cells are pluripotent stem cells, which are obtained by reprogramming of somatic 
tissues. They provide unique opportunities in biomedical research, including disease 
modeling, drug development and cellular therapy, all of which is critically dependent 
on their in vitro differentiation capacity. However, in vitro differentiation of iPS cells 
is still challenging, in particular towards mesendoderm lineages, such as 
hematopoietic cells, hepatocytes and pancreatic cells (Feng et al., 2010; Narsinh et al., 
2011; Robinton and Daley, 2012).  
 
Cell fusion occurs as a physiological phenomenon in our body, when cells need to 
increase their functional property. When a somatic cell is fused with a pluripotent 
stem cell, the somatic genome can be reprogrammed into a pluripotent state. Previous 
studies applied cell fusion as a tool to study reprogramming, which is driven by the 
pluripotent fusion partner. However the impact of somatic cells on the differentiation 
capacity of the pluripotent fusion partner is still elusive. Given that somatic cells bear 
developmental “codes”, we hypothesize that the somatic genome might contribute to 
differentiation of such hybrids, and thus might serve as an enhancer for pluripotent 
stem cell differentiation (Fig. 1.18). 
 
Fig. 1.18 Aim of cell fusion study. By fusing somatic cells with pluripotent stem cells, somatic 
genome is reprogrammed into a pluripotent state. However, the differentiation capacity of the hybrids 
is largely unknown. We assumed that the differentiation property of hybrids is influenced by the 
somatic fusion partner. 
 
Even though mouse cells share many similarities as human counterparts, potential 
clinical application developed from mouse research model must be tested in human 
system. In previous studies, biomaterial (LR704) and small molecule (EBIO) showed 
an enhancing effect on cardiomyocyte differentiation of mouse ES cells. However, 
whether the same activity could also be observed in human stem cells is not clear. 
 
The aim of this study is to improve human iPS cell differentiation through different 
approaches, including cell fusion, biomaterial (LR704) and small molecule (EBIO). 
We fused human iPS cells with HSC from cord blood to generate pluripotent 
iPS/somatic cell hybrids, in the following referred as iPS hybrids. Pluripotency of 
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such iPS hybrids was assessed. Differentiation property of iPS hybrids was analyzed 
both in vitro and in vivo, in comparison to parental iPS cells. Functional analysis of 
differentiated cells from iPS hybrids was performed. Additionally, the underlying 
mechanism, which causes the distinct differentiation capacity of iPS hybrids, was 
analyzed. Finally, we investigated the cardiomyocyte differentiation of human iPS 
cells by using either LR704 or EBIO. 
 
Mostly out of habit and to honor the fact that research is rarely an entirely solitary 
process, I will mostly rely on the use of we in the following text. 
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2 Materials 
2.1 Chemicals and solutions 
Table 2.1 List of biologicals and chemicals used in this study 
Name Catalog number Manufactures 
Gelatin # G-1890 Sigma-Aldrich 
BD Matrigel hESC-qualified 
Matrix 
# 354277 BD Biosciences 
Poly-orthinine (PO) # P3655 Sigma-Aldrich 
Laminin (LA) # 23017-015 Invitrogen 
Ficoll-Hypaque # J00412-2079 GE Healthcare 
Chondroitin-6-sulfate 
sodium salt (CSC) 
# C4384 Sigma-Aldrich 
Polybrene # H9268 Sigma-Aldrich 
50% Polyethylene glycol 
4000 (PEG 4000) 
# EL0011 Fermentas 
KaryoMAX Colcemid™ 
Solution 
# 15210-040 Invitrogen 
EBIO # 1041 Tocris bioscience 
Puromycin # 58-58-2  Sigma 
Hygromycin B # 10687-010 Invitrogen 
 
2.2 Commercial kits 
Table 2.2 List of commercial kits 
Name Catalog number Manufactures 
NucleoSpin Gel and PCR 
Clean-up kit 
# 1110/001 Macherey-Nagel 
NucleoSpin Plasmid kit # 1202/004 Macherey-Nagel 
NucleoBond Xtra Maxi kit # 1209/001 Macherey-Nagel 
NucleoSpin RNA II kit # 1302/005 Macherey-Nagel 
CD34 MicroBead kit # 130-046-702 Miltenyi Biotec 
High Capacity cDNA 
Reverse Transcription kit 
# 4368814 Applied Biosystems 
LDL Uptake Assay Kit 
(Cell-Based) 
# ab133127 
 
Abcam 
 
Urea Colorimetric Assay 
Kit 
# K375-100 
 
BioVision 
 
Periodic Acid-Schiff (PAS) 
Kit 
# 395B 
 
Sigma 
WT Expression Kit for 10 
reactions 
# 44 11 973 
 
Ambion  
 
WT Terminal Labeling and 
Control Kit (10reactions) 
# 901 525 
 
Affymetrix 
 
GeneChip Human Gene 
1.0ST Array 
# 901 085 
 
Affymetrix 
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2.3 Instruments  
Table 2.3 List of Instruments 
Name Manufactures 
FACSCanto BD Biosciences 
Leica DM RXA RF8 epifluorescence 
microscope 
Leica 
NanoDrop 1000 Thermo 
Axiovert 200 microscope Carl Zeiss 
Autostainer Dako cytomation 
StepOne Real-Time PCR system Applied Biosystems 
Bioruptor Diagenode 
 
2.4 Primers for RT-qPCR 
All primers were ordered at Eurofins (Luxembourg) and provided in Appendix (Table 
8.1 and Table 8.2).  
 
2.5 Enzymes and enzyme inhibitors 
Table 2.4 List of enzymes and inhibitors 
Name Manufactures 
Restriction enzymes (XbaI, BamHI, ClaI) Fementas 
pfu polymerase Fermentas 
T4 ligase Fermentas 
Fast SYBR Green Master Mix Applied Biosystems 
Trypsin Invitrogen (#15400-054) 
Collagenase IV Invitrogen (#17104-019) 
Alfazyme PAA (#L11-012) 
Rho-kinase inhibitor Y27632 Ascent-Scientific (#Asc-129) 
Accutase Stemcell Technologies (#AT104) 
Dispase Stemcell Technologies (#07923) 
SB431542 Tocris bioscience (#1614) 
  
2.6 Cytokines and growth factors for cell culture 
Table 2.5 List of cytokines and growth factors 
Name Stock concentration Manufactures 
Basic fibroblast growth 
factor (bFGF) 
100 µg/mL (10,000x) PeproTech (#100-18B) 
Stem cell factor (SCF) 100 µg/mL (1,000x) PeproTech (#300-07) 
IL-6/soluble IL-6R fusion 
protein (hyper-IL-6) 
25 µg/mL (2,500x) A generous gift from S. 
Rose-John, Kiel, Germany 
FLT-3 ligand 25 µg/mL (500x) PeproTech (# 300-19) 
Troponin (TPO) 20 µg/mL (1,000x) PeproTech (#AF300-18) 
Epidermal growth factor 
(EGF) 
100 µg/mL (10,000x) PeproTech (#PHG0315) 
Recombinant human 
vascular endothelial 
100 µg/mL (2,500x for 
endothelial cells; 10,000x 
PeproTech (#100-20) 
	  	  	   25	  
growth factor (VEGF) for hematopoietic 
differentiation) 
Insulin-like growth factor 
(IGF-1) 
40 µg/mL (1,600x) Sigma-Aldrich 
IL-3 150 µg/mL (5,000x) Miltenyi Biotec (#130-
093-908) 
Bone morphogenetic 
protein 4 (BMP4) 
25 µg/mL (2,500x) Miltenyi Biotec  
(# 130-098-786) 
 
2.7 Eukaryotic cells 
Table 2.6 List of cell types  
Name Definition 
MEF Mouse embryonic fibroblasts 
HEK293T cells Human embryonic kidney cells 
iLB c1-30m-r12 
(referred to as iPS cells) 
Human induced pluripotent stem cells derived from 
human foreskin fibroblasts by retrovirus 
(OCT4/SOX2/KLF4/c-MYC), kindly provided by 
Michael Peitz and Prof. Oliver Brüstle, Life & Brain 
GmbH, Bonn, Germany. 
Human iPS_37 cells 
(referred to as iPS_2 cells) 
Human induced pluripotent stem cells derived from 
human fibroblasts by sendai virus 
(OCT4/SOX2/KLF4/c-MYC), kindly provided by 
Stephanie Sonntag, Institute for Biomedical 
Engineering-Cell Biology, RWTH Aachen University, 
Aachen, Germany. 
M4C4 human iPS cells Human induced pluripotent stem cells derived from 
human mesenchymal stem cells by retrovirus 
(OCT4/SOX2/KLF4/c-MYC), kindly provided by Prof. 
Wolfgang Wagner, Helmholtz Institute for Biomedical 
Engineering, Stem Cell Biology and Cellular 
Engineering, RWTH Aachen University, Aachen, 
Germany, and Prof. Tomo Saric, Institute for 
Neurophysiology, University of Cologne School of 
Medicine, Germany. 
H9 human ES cell line Human embryonic stem cells, purchased from WiCell, 
USA. 
Cord bloods Bloods isolated from neonatal umbilical cord. 
Human fibroblasts (hFi) Both were derived from healthy donors and were kindly 
provided by Hatim Hemeda and Prof. Wolfgang 
Wagner, Helmholtz Institute for Biomedical 
Engineering, Stem Cell Biology and Cellular 
Engineering, RWTH Aachen University, Aachen, 
Germany. 
Human mesenchymal stem 
cells (hMSC) 
 
2.8 Plastic dishes for cell culture 
Table 2.7 List of tissue culture materials 
Name Manufactures 
Ultra low attachment 
dishes 
Corning Life Sciences 
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Petri dishes Nunc 
6-well plate Nunc 
15 cm tissue culture dishes Nunc 
10 cm tissue culture dishes Nunc 
AggreWell Stemcell Technologies 
 
2.9 Reagents for cell culture 
Table 2.8 Reagents for tissue culture 
Name Catalog number Manufacture 
KnockOut DMEM # 10829018 Invitrogen 
KnockOut Serum 
Replacement 
# 10828028 Invitrogen 
Non essential amino acid # 11140 Invitrogen 
Pen/Strep (100x) # 15140 Invitrogen 
L-Glutamine (100x) # 25030 Invitrogen 
β-Mercaptoethanol (50 
mM) 
# 31350 Invitrogen 
High glucose DMEM # 41965 Invitrogen 
Low glucose DMEM # 1230224 Invitrogen 
DMEM/F12 # 11330-032 Invitrogen 
StemPro34 # 10639-11 Gibco 
DMSO # D4540 Sigma-Aldrich 
Fetal calf serum (FCS) in 
spontaneous differentiation 
medium 
# 9SB026 Lonza 
FCS in hematopoietic 
differentiation 
# 531K Gibco 
FCS in MEF medium # 41F6504K Invitrogen 
FCS in HEK293T medium # A11-151 PAA 
mTeSR1 basal medium # 05851 Stemcell Technologies 
5×Supplement medium # 05852 Stemcell Technologies 
StemSpan medium # 09600 Stemcell Technologies 
N2 supplement # 17502-048 Invitrogen 
B27 supplement # 17504-044 Invitrogen 
Monothioglycerol (MTG) # M1753 Sigma-Aldrich 
Transferrin # T0665 Sigma-Aldrich 
L-ascorbic acid (L-AA) # A4403 Sigma-Aldrich 
StemMACS HSC-CFU  
Media 
# 130-091-280 Miltenyi Biotec 
 
2.10 Medium composition for cell culture 
Medium composition was provided in Appendix (8.2). 
 
2.11 Buffers 
1) Phosphate-buffered saline (PBS) (PAA) 
2) Washing buffer for HSC isolation (PBS+2 mM EDTA) 
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EDTA (0.5 M, 2 mL) is added to 500 mL PBS 
3) Magnetic activated cell sorting (MACS) buffer 
Bovine serum albumin (BSA, 2.5 g) and EDTA (0.5 M, 2 mL) are added into 500 
mL PBS. Store at 4°C.  
4) FACS Buffer 
BSA (5 g) is dissolved in 500 mL PBS. Store at 4°C. 
5) 10x transfer buffer 
Trizma base (30.3 g) and glycine (144 g) are dissolved in 1 L H2O. Store at RT.  
6) 10x running buffer 
Trizma base (30.3 g), glycine (144 g) and SDS (10 g) are dissolved in 1 L H2O.    
Store at RT. 
    
2.12 Antibodies 
Table 2.9 List of antibodies 
Name Catalog number Manufacture 
OCT-3/4 # sc-9081 Santa Cruz Biotechnology 
SSEA4 # MAB4304 Millipore 
TRA-1-60 # MAB4360 Millipore 
cTnT # MAB1874 R&D 
NESTIN # ab5922 Millipore 
TUJ-1 # MAB1195 R&D 
AFP # MAB1368 R&D 
ALB # MAB1455 R&D 
CD43-Bio # DF-T1 Miltenyi Biotec 
CD31-PE # 555446 BD Pharmingen 
CD45-biotin # 557833 BD Pharmingen 
CD34-APC # 555824 BD Pharmingen 
CD14-PE # 347497 BD Pharmingen 
FLT3-APC # 17135742 eBioscience 
CD11c-PE-Cy7 # 25011642 eBioscience 
NODAL # AB4334 Millipore 
p-SMAD2 # 3101S Cell Signaling Technology 
ACTIN # A5316 Sigma-Aldrich 
Peroxidase conjugated 
anti-rabbit (2nd Ab for 
western blotting) 
# NA934V GE Healthcare 
Peroxidase conjugated 
anti-mouse (2nd Ab for 
western blotting) 
# NA931 GE Healthcare 
Hoechst 33258 # 861405 Sigma-Aldrich 
H3K27me3 # pAb-069-050 Diagenode 
H3K4me3 # pAb-003-050 Diagenode 
Alexa Fluor 594 # A11005  Invitrogen 
 
2.13 Bacteria E.coli strain 
DH5α E.coli competent strain is used for transformation.  
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2.14 Biomaterials 
All biomaterials were purchased from Boehringer Ingelheim Pharma GmbH & Co. 
KG. When we planed the experiment, the company stopped producing LR704 
(IUPAC name: Poly(L-lactide-co-D,L-lactide)), but provided other products with the 
same molecule formula (LR704S, LR706S and LR708). These three biomaterials are 
different in inherent viscosity.  
Table 2.10 Biomaterials 
Product name Material No. 
RESOMER LR704S 65054 
RESOMER LR706S 65055 
RESOMER LR708 60640677 
 
2.15 Animals 
Animals were bred and maintained under specific pathogen-free condition at the 
Animal Facility of RWTH Aachen University Hospital. CD1 mice were provided in 
house and used for MEF preparation. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) 
mice were obtained from A. M. Müller, center for Experimental Molecular Medicine, 
University of Würzburg, Würzburg, Germany and used in teratoma assay. All 
experimental procedures involving animal work were approved by local authorities, in 
compliance with the German animal protection law. 
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3 Methods  
3.1 Vector construction  
 
The pFUGIEpuro vector contains the puromycin resistance (puro) and enhanced green 
fluorescent protein (eGFP) genes (see below Fig. 4.2A) to allow antibiotic and GFP 
selection of hybrid clones. 
 
We used pFUGIE (a kind gift from Filip Farnebo, Karolinska Institute, Stockholm, 
Sweden) as backbone vector, which contains the human ubiquitin C promoter (UbC) 
and the internal ribosome entry site (IRES) for expression of eGFP. For introducing 
puro into pFUGIE vector between UbC promoter and IRES region, we amplified the 
puro fragment from pMSCVpuro vector by PCR. To allow cloning of puro fragment 
in XbaI and BamHI sites between UbC promoter and IRES in pFUGIE vector, we 
incorporated the respective restriction enzyme sites (XbaI: TCTAGA; BamHI: 
GGATCC) into the primer sequence for amplifying puro fragment from pMSCVpuro 
vector.  
 
Forward primer: 5’-TGCTCTAGAGCCCAAGCTTACCATGACCGA-3’ 
Reverse primer: 5’-CGGGATCCCGCGTCAGGCACCGGGCTT-3’   
 
3.1.1 Polymerase chain reaction (PCR) 
 
PCR reaction was performed in thermal cycling machine with pfu polymerase 
(Fermentas). The reaction system consisted of:  
 
10x pfu buffer with MgSO4         5 µL 
10mM dNTP mix                 5 µL 
10µM forward and reverse primer    1 µL 
pfu polymerase                   1 µL (2 U) 
DNA template                   0.5 µL (300 ng) 
H2O up to 50 µL 
 
PCR amplification condition: 
95°C       3 min 
95°C       30 sec 
57°C -72°C  30 sec +0.5°C /cycle            30 cycles 
 72°C       2min 
 72°C       5min 
 4°C  
 
PCR products were checked by electrophoresis on 1.5% agarose gel and purified by 
NucleoSpin Gel and PCR Clean-up kit according to manufacturer’s instruction. 
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3.1.2 Restriction enzyme digestion and ligation 
 
pFUGIE backbone vector and puro PCR fragment were digested with XbaI and 
BamHI enzymes for 2 hours at 37°C. Reaction mix contained: 
 
10x buffer           5 µL 
DNA 4 µL 
XbaI enzyme        1.5 µL 
BamHI enzyme      1.5 µL  
H2O up to 50 µL 
 
Vector and PCR fragment were purified by NucleoSpin Gel and PCR Clean-up kit and 
ligation was performed with T4 ligation kit overnight at room temperature (RT). 
Ligation mix contained: 
 
10x buffer           2 µL 
pFUGIE DNA         5 µL 
puro DNA            10 µL 
T4 ligase             1 µL  
H2O up to 20 µL 
 
Ligation products were then purified by NucleoSpin Gel and PCR Clean-up kit, and 
checked by electrophoresis on 1.2% agarose gel. 
 
3.1.3 Transformation of DH5α E.coli 
 
Ligation product (2 µL) was added into 100 µL competent DH5α and incubated on ice 
for 30 min. DH5α were then subjected to heat shock for 30 sec at 42°C and incubated 
on ice for 2 min. LB medium (250 µL) was added gently and DH5α were incubated in 
a shaker for 1-2 hours at 37°C. Transformation product (100 µL) was plated onto 10 
cm LB culture dish with 50 µg/mL ampicillin and incubated overnight at 37°C. 
 
In the following day, 30 clones were picked and expanded with 5 mL LB medium 
overnight at 37°C. Plasmid DNA was isolated by NucleoSpin Plasmid kit and clones 
were screened by digestion with Xbal and Cla1 or with Xbal and BamH1 and checked 
by electrophoresis to identify pFUGIEpuro. 
 
3.1.4 Isolation of plasmid DNA 
 
DH5α clones containing pFUGIEpuro were expanded in 5 mL LB medium (50 µg/mL 
ampicillin) for 12 hours at 37°C in the shaker, then transferred into 1 L LB medium 
and incubated for another 12 hours in the shaker. In the following day pFUGIEpuro 
plasmid DNA was isolated by NucleoBond Xtra Maxi kit according to manufacturer’s 
instruction. Quality and concentration of plasmid DNA was determined by NanoDrop 
1000 (Thermo). 
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3.1.5 Testing of pFUGIEpuro in HEK293T cells 
 
To test pFUGIEpuro, lentivirus was generated by calcium phosphate transfection and 
was used to infect HEK293T cells. Briefly, HEK293T cells were cultured on 0.1% 
gelatin coated 10 cm dish. When cells reached 60% confluence, complete culture 
medium change was performed 1 hour before transfection. Plasmid DNA, packaging 
vectors and CaCl2 were added and mixed as below: 
 
Plasmid DNA                5 µg 
pMD2G-vsvg               1.25 µg 
pCMV-R8.74               3.75 µg 
2M CaCl2                  62.5 µL 
H2O up to 250 µL 
 
Plasmid mixture was added dropwise into 2x Hepes Buffered Saline (HBS; 250 µL) 
while vortexing. Transfection mixture was incubated at RT for 30 min, then added 
into HEK293T cells.  
 
Lentivirus was harvested 72 hours after transfection. Supernatant from HEK293T 
culture was collected, centrifuged (1,200 rpm, 4 min) and filtered through a 0.45 µm 
pore-sized polyethersulfone membrane. Concentration of lentivirus was performed by 
precipitation with chondroitin-6-sulfate sodium salt (CSC; 80 µg/mL) and polybrene 
(80 µg/mL) for 30 min at RT and centrifugation at 3,000 rpm for 20 min (Landazuri et 
al., 2006). Lentivirus was resuspended with PBS and added into HEK293T culture 
together with 8 µg/mL polybrene. Lentivirus was removed from culture medium the 
next day and puromycin selection (4-8 µg/mL) was performed 72 hours after 
infection.   
 
3.2 Cell culture 
3.2.1 Culture of HEK293T cells 
 
HEK293T cells were maintained in high glucose DMEM (Invitrogen) supplemented 
with 10% FCS (GE Healthcare), 1% L-Glutamine, 1% Pen/Strep (see 8.2) on 0.1% 
gelatin coated culture dishes. For coating dishes, 5 mL 0.1% gelatin solution was 
added into 10 cm dish and incubated for 30 min at 37°C. For passaging, cells were 
washed three times with PBS and subjected to 3 mL 0.05% trypsin treatment. After 
incubation for 2 min at 37°C, trypsin reaction was stopped by culture medium 
containing FCS (3 mL). Cells were collected into 15 mL Falcon tubes and centrifuged 
at 1,200 rpm for 4 min. Cells were split at 1:5 ratio into gelatin coated dishes. 
Passaging was performed every three days.  
 
3.2.2 Mouse embryonic fibroblast (MEF) preparation 
 
Pregnant CD1 (E13.5-15.5) mice were sacrificed by cervical dislocation and abdomen 
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was opened. Uterus was dissected with scissor and put into 50 mL Falcon tube filled 
with PBS. The uterus was incubated with 1% Pen/Strep solution and transferred into 
10 cm petri dish supplied with PBS. Each embryo was isolated from extraembryonic 
tissues and transferred into another 10 cm petri dish supplied with PBS. Head, limbs, 
abdominal organs and tail were dissected and removed from the main body. The 
residual embryo was transferred into 10 cm petri dish supplied with 0.5 mL PBS and 
cut into small pieces with scissor. Embryonic clumps were then transferred into a 15 
mL Falcon tube and mixed well with 3 mL 0.05% trypsin. After incubation for 3-5 
min at 37°C, supernatant was collected into a new Falcon tube and trypsin reaction 
was stopped by mixing with MEF culture medium (see 8.2). Another 3 mL trypsin 
was added to the original tube containing embryonic clumps, and clumps were 
incubated again for another 3-5 min in the incubator. The above procedure was 
repeated 3-5 times until all embryonic clumps were dissociated into single cells or 
smaller clumps. All MEF were collected by centrifugation at 1,200 rpm for 4 min and 
seeded in 15 cm culture dishes (1-2 embryo/dish).  
 
When MEF reached confluence, cells were split with 0.05% trypsin similar as 
HEK293T cell culture (see above) and cultured in MEF culture medium (see 8.2). 
Passage 3 (P3) MEF were ready for irradiation. MEF were harvested, irradiated by 30 
Gy (3000 rads) γ-ray and frozen in medium supplemented with 10% DMSO (4x106 
cells per cryotube) and stored in liquid nitrogen.  
 
3.2.3 Culture of human iPS and ES cells on MEF 
 
In this study, we used two human iPS cell lines. (i) iLB c1-30m-r12 (Koch et al., 
2011) (referred to as iPS cells; Table 2.6), which was derived from fibroblast with 
human OCT4, SOX2, KLF4, c-MYC in retrovirus. (ii) human iPS_37 (referred to as 
iPS_2 cells; Table 2.6), derived with human OCT4, SOX2, KLF4, c-MYC in Sendai 
virus by Stephanie Sontag. Hybrids were cultured with the same culture condition as 
human iPS and ES cells (see 8.2). 
 
One day before thawing human iPS or ES cells, MEF were thawed and seeded into 
0.1% gelatin coated 6-well plate. Before thawing, culture medium (9 mL; see 8.2) was 
added to a 15 mL Falcon tube and water bath was set at 37°C. One frozen cryotube of 
cells was taken from the liquid nitrogen tank and thawed immediately in water bath. 
When there was still a frozen cell pellet inside, cryotube was taken out from the water 
bath, wiped with 70% ethanol and cells were gently transferred into Falcon tube 
containing culture medium. After centrifugation at 1,200 rpm for 4 min, cells were 
resuspended with culture medium contaning KnockOut DMEM, 20% KnockOut 
Serum Replacement, 0.1 mM β-mercaptoethanol, 1% nonessential amino acids, 1% 
Pen/Strep, 8-10 ng/ml human basic fibroblast growth factor (bFGF; see 8.2) and 
seeded into 0.1% gelatin coated 6-well plate. Medium change was performed on daily 
basis.  
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For passaging, iPS or ES cells were subjected to Collagenase IV (1 mg/mL) treatment 
for 20-40 min at 37°C. When 80% of the colonies detached from the culture plate, 
Knockout DMEM was added to rinse the detached colonies. Cell clumps were 
collected into 15 mL Falcon tube. After centrifugation at 1,000 rpm for 4 min, cell 
clumps were resuspended with 1 mL culture medium. After pipetting up and down for 
20-30 times with 1 mL pipette tip, small colony clumps were seeded at 1:3 ratio into 
new culture plate. Normally cell passage was performed every three days, depending 
on the size and density of iPS or ES colonies. Colonies, which are either too big or 
over confluent, tend to differentiate.  
 
For freezing, cells were subjected to Alfazyme treatment for 10 min at 37°C. Single 
cells were then collected and centrifuged at 1,200 rpm for 4 min. Cells were 
resuspended with cryopreservation medium containing with 10% DMSO (see 8.2) and 
Rho-kinase inhibitor Y27632 (10 µM) and kept overnight at -80°C. The next day 
cryotubes were transferred to liquid nitrogen.   
 
3.2.4 Culture of human iPS and ES cells in feeder-free condition 
 
For cell fusion, pluripotent stem cells were maintained in feeder-free condition to 
avoid MEF contamination. After puromycin selection, hybrid clones were switched 
back to MEF culture condition.  
 
In feeder-free culture condition, pluripotent stem cells were grown on Matrigel coated 
6-well plate and supplied with mTeSR1 medium (see 8.2). For coating Matrigel 
plates, Matrigel aliquot was thawed overnight at 4°C and tissue culture plates/dishes 
were also pre-cooled (4°C). Matrigel was diluted with 25 mL cold KnockOut DMEM, 
added to tissue culture plates/dishes (1 mL /well in 6-well plate; 3 mL /10 cm dish) 
and incubated for 30 min at 37°C. Human iPS or ES cells can be transferred from 
MEF culture condition into feeder-free condition directly. Medium change was also 
performed on daily basis with mTeSR1 medium.  
 
For passaging, cells were subjected to Dispase treatment for 10 min at 37°C. When 
colonies were about to detach from culture plate, Dispase was removed and 
KnockOut DMEM was added to wash away residual enzyme for three times. After 
adding fresh mTeSR1 medium to culture plate, pipette tip (1 mL) was used to 
dissociate colonies into small pieces. Then cell clumps were transferred into new 
Matrigel coated plate (split ratio 1:3-6). For passaging cells as single cells, Accutase 
was applied to colonies for 5 min at 37°C. After Accutase treatment, KnockOut 
DMEM was added to rinse and collect single cells and cells were centrifuged at 1,200 
rpm for 4 min. Cell pellet was resuspended with mTeSR1 medium supplemented with 
Rho-kinase inhibitor Y27632 (10 µM) and seeded onto new Matrigel coated plate 
(split ratio 1:8-10).  
 
	  	  	   34	  
3.2.5 Isolation and expansion of CD34+ cord blood cells 
 
Umbilical cord blood samples were harvested according to the guidelines approved by 
the Ethic Committee of Medical Faculty, RWTH Aachen University (permit number: 
EK187/08).  
 
Umbilical cord blood (50 mL) was collected and diluted with ice cold washing buffer 
(PBS+2 mM EDTA). Diluted cord blood was then added gently into 50 mL Falcon 
tubes containing Ficoll-Hypaque solution (15 mL). After centrifugation at 2,000 rpm 
for 20 min, mononuclear cells were carefully collected with 5 mL pipette. Cells were 
washed three times with ice cold washing buffer and enriched for CD34+ HSC by 
magnetic activated cell sorting (MACS) CD34 MicroBead kit according to the 
manufacturer’s instruction. CD34+ HSC were cultured in StemSpan medium 
supplemented with 100 ng/mL SCF, 50 ng/mL FLT-3 ligand, 20 ng/mL TPO and 10 
ng/mL hyper-IL-6 (see 8.2). Medium was changed every other day.  
 
3.2.6 In vitro differentiation  
 
For spontaneous differentiation, undifferentiated human iPS, ES cells and hybrids 
were dissociated with Collagenase IV for 20-40 min at 37℃. Cell clumps were 
harvested and cultured with differentiation medium containing KnockOut DMEM  
supplemented with 20% FCS (see 8.2) in 10 cm ultra low attachment dish (see 2.7) to 
form EB. On day 7 of differentiation, EB were plated on 0.1% gelatin-coated 10 cm 
dish and cultured for another 7-14 days. 
 
To assess cardiomyocytes differentiation, individual EB (day 7) were isolated and 
seeded into 0.1% gelatin coated 96-well plates (2-3 EB/well, 8 wells/group). On day 
14 of differentiation, beating areas were counted. Percentage of beating areas = 
(number of wells containing beating areas/ total well number) x 100%. Analysis was 
done in triplicates. 
 
For neural differentiation, undifferentiated cell clumps were cultured with neural 
differentiation medium I containing KnockOut DMEM and 20% KnockOut serum 
replacement (see 8.2) in 10 cm Petri dish to form EB. On day 7, EB were then plated 
in 6-well plate coated with Poly-L-ornithine (PO) and Laminin (LA), and cultured 
with neural differentiation medium II containing DMEM/F12, N2 supplement, B27 
supplement, bFGF (10 ng/mL) and EGF (10 ng/mL; see 8.2) for 7 days. Neural 
differentiated cells were further culture with neural differentiation medium III 
containing DMEM/F12, N2 supplement, B27 supplement without growth factors (see 
8.2) for another 7 days. 
 
For hematopoietic differentiation, we applied stepwise differentiation protocol 
modified from previous publications (Kennedy et al., 2012). In brief, undifferentiated 
cells were harvested by collagenase IV treatment and cultured in hematopoietic 
	  	  	   35	  
differentiation medium I containing basal medium supplemented with 10 ng/mL 
BMP4 and 50 µg/mL L-AA (see 8.2). On day 1 of differentiation, hematopoietic 
differentiation medium II was applied, containing basal medium supplemented with 
10 ng/mL BMP4, 10 ng/mL bFGF and 50 µg/mL L-AA (see 8.2). On day 2 of 
differentiation, hematopoietic differentiation medium III was applied, containing 
basal medium supplemented with 10 ng/mL BMP4, 10 ng/mL bFGF, 50 µg/mL L-
AA , 10 ng/mL VEGF, 100 ng/mL SCF, 10 ng/mL hyper-IL-6 and 25 ng/mL IGF-1 
(see 8.2). On day 4 of differentiation, hematopoietic differentiation medium IV was 
applied, containing basal medium supplemented with 10 ng/mL bFGF, 10 ng/mL 
VEGF, 100 ng/mL SCF, 10 ng/mL hyper-IL-6, 25 ng/mL IGF-1, 30 ng/mL IL-3, 20 
ng/mL TPO and 10 ng/mL FLT-3 ligand (see 8.2). From day 6 to day 14, cells were 
maintained in hematopoietic differentiation medium V, containing basal medium 
supplemented with 100 ng/mL SCF, 30 ng/mL IL-3, 20 ng/mL TPO and 10 ng/mL 
FLT-3 ligand (see 8.2). From day 14 to day 21, cells were induced to dendritic cell 
lineage by hematopoietic differentiation medium VI, containing basal medium 
supplemented with 100 ng/mL FLT-3 ligand and 10% FCS (see 8.2). 
 
For differentiation on biomaterials, experiments were based on spontaneous 
differentiation. Briefly, EB were formed in suspension culture in ultra low attachment 
dishes/plates for 7 days (see above), then seeded onto gelatin coated biomaterials and 
continued to culture for another 7-14 days. Gelatin (0.1%) coated tissue culture plates 
were used as control.  
 
EBIO experiments were also based on spontaneous differentiation method. In brief, 
0.1 mM EBIO (containing 0.01% DMSO, see Table 2.1) was added to the 
differentiation medium from day 0-7 of EB development, and medium change was 
performed every two days. After 7 days of suspension culture, EB were seeded into 
gelatin (0.1%) coated 6-well plate and continued culture without EBIO treatment for 
another 7-14 days.  
 
3.2.7 Culture of human MSC and fibroblasts 
 
hMSC were maintained in low glucose-DMEM supplemented with 10% FCS (PAA), 
1% L-Glutamine, 1% Pen/Strep (see 8.2) on 10 cm tissue culture dish. Medium 
change was performed in every second day. On passaging, culture medium was 
removed and cells were washed three times with 1xPBS, subjected to 3 mL 0.05% 
trypsin treatment. After incubation at 37°C for 1 min, trypsin reaction was stopped by 
3 mL culture medium containing FCS and cells were harvested into 15 mL Falcon 
tubes, centrifuged at 1,200 rpm for 4 min. Cells were split as 1:3-5 ratio every three 
days.  
 
Human fibroblasts (hFi) were maintained in high glucose-DMEM supplemented with 
10% FCS (both Invitrogen), 1% L-Glutamine, 1% Pen/Strep (see 8.2) on 10 cm tissue 
culture dish. Culture protocol was similar to hMSC culture. 
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3.3 Cell fusion 
3.3.1 Lentivirus production and transduction 
 
Lentivirus production was performed by calcium phosphate transfection into 
HEK293T cells (15 cm dish) as above (see 3.1.5), but with more DNA and in larger 
transfection volume.  
 
Plasmid DNA                25 µg 
pMD2G-vsvg               6.25µg 
pCMV-R8.74               18.75µg 
2M CaCl2                  125 µL 
H2O up to 1 mL 
 
Plasmid mixture was added into 1 mL 2xHBS. Lentivirus particles were harvested, 
resuspended in 300 µL PBS and added with 8 µg/mL polybrene into CD34+ HSC 
culture. Lentivirus was removed from HSC culture 48 hours later by Ficoll density 
gradient centrifugation.   
 
3.3.2 Cell fusion 
 
To produce hybrid cells, human iPS or ES cells maintained in feeder-free condition 
were dissociated into single cells by Accutase. iPS/ES cells (2x106) were mixed with 
HSC (4x106), centrifuged at 1,200 rpm for 4 min. Then 400 µl PEG 4000 was added 
dropwise to cell pellet. Cells were incubated for 3 min at 37°C and 14 mL mTeSR1 
culture medium supplemented with Rock-kinase inhibitor Y27632 (10 µM) was added 
slowly. Cells were recovered by centrifugation (1,200 rpm, 4 min) and seeded onto 
Matrigel-coated dishes in mTeSR1.  
 
3.3.3 Puromycin selection of hybrid clones  
 
Puromycin (4-8 µg/mL) was added 48 hours after fusion for one day. Puromycin 
resistant hybrid clones were picked 1 week later and transferred to MEF culture 
conditions for further analysis.  
 
3.4 Flow Cytometry 
 
DNA content (2n and 4n) was determined by flow cytometry. Cells were dissociated 
with accutase for 5-10 min at 37°C and passed through a 30 µm cell strainer (BD 
Biosciences) to obtain single cells. Cells were stained with Hoechst 33258 for 10 min 
at 4°C, washed twice in FACS buffer, resuspended in 500 µL FACS buffer and 
measured by FACSCanto. 
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To analyze the expression of hematopoietic cell markers, single differentiating cells 
were dissociated by Trypsin (Invitrogen) treatment and stained with primary 
antibodies for 30 min at 4℃. After wash with FACS buffer, cells were incubated with 
secondary antibody for 30 min at 4℃, washed and measured by FACSCanto. The 
following antibodies were used: CD34-APC (1:100), CD45-biotin (1:100), CD14-PE 
(1:50; all from BD Bioscience), FLT3-APC (1:50), CD11c-PE-Cy7 (1:100; both from 
eBioscience, San Diego, CA), CD43-Bio (1:100) and and anti-biotin-VioBlue (1:100; 
Miltenyi Biotec). 
 
3.5 Multicolor fluorescence in situ hybridization analysis (M-FISH) 
 
M-FISH analysis was performed in collaboration with Prof. Anna Jauch, Institute of 
Human Genetics, University Heidelberg, Heidelberg, Germany. Briefly, subconfluent 
iPS and hybrids were arrested in metaphase by KaryoMAX Colcemi Solution (0.1 
µg/mL, Invitrogen) for 2 h at 37°C. Single cells were obtained by trypsin treatment (5 
min, 37°C), and 75 mM KCl was added. After 20-30 min incubation at 37°C, samples 
were centrifuged at 1,200 rpm for 5 min and the cell pellet was fixed with 
methanol/acetic acid (3:1, vol:vol) by pipetting. Cells were subjected to three 
consecutive cycles of washing and fixation with methanol/acetic acid (3:1) and 
analyzed by in situ hybridization.  
 
For M-FISH analysis, human chromosome-specific painting probes were 
combinatorially labeled by using seven different fluorochromes and hybridized as 
previously described (Jentsch et al., 2003). For each cell line, 25 metaphase spreads 
were acquired by using a Leica DM RXA RF8 epifluorescence microscope equipped 
with a Sensys CCD camera. Camera and microscope were controlled by the Leica Q-
FISH software. Metaphase spreads were processed on the basis of the Leica MCK 
software and presented as multicolor karyograms. 
 
3.6 RT-qPCR and ChIP-qPCR 
 
Total RNA was isolated with NucleoSpin RNA II kit. RNA quality and concentration 
were determined by NanoDrop 1000. RNA (1 µg) was used as template for reverse 
transcription with High Capacity cDNA Reverse Transcription kit. Quantitative (q) 
PCR was carried out with StepOne Real-Time PCR system. Reactions were 
performed with 50 ng cDNA, fast SYBR Green PCR master mix and primers. The 
calculated threshold cycle (Ct) value for each sample was normalized against the 
corresponding GAPDH value. The relevant expression values were subjected to 
hierarchical clustering analyzed by the MultiExperiment Viewer (MeV, TM4.7.4; 
http://www.tm4.org/mev/). Briefly, for generating heat maps in MeV, △Ct value [△
Ct=Ct (gene of interest)  – Ct (GAPDH)] was normalized as follows Z score=[△Ct 
value – mean (Row)] / standard derivation (Row) and Z scores were subjected to 
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clustering analysis. Therefore each color code represents not the fold differences, 
rather than the Z score differences of gene expression. For all the color code, red 
indicates high gene expression and green indicates low gene expression.  
 
For ChIP-qPCR analysis, we applied the protocol described by Dahl, J. A. et al. with 
some modifications (Dahl and Collas, 2008). In brief, samples were fixed with 1% 
formaldehyde for 10 min at RT, quenched with glycine and washed with PBS for 
three times. Samples were resuspended in lysis buffer, sonicated for 10 min at 4°C in 
Bioruptor and centrifuged for 10 min. Supernatant was incubated with polyclonal 
antibodies to H3K4me3, H3K27me3 and normal rabbit serum (Santa Cruz 
Biotechnology, USA). DNA-protein complexes were collected using protein-A 
Dynabeads (life technologies, Darmstadt, Germany). DNA was decross-linked and 
purified using NucleoSpin Gel and PCR Clean-up kit. qPCR was applied to detect the 
enrichment of histone modification at different genes. Input control was 10% of 
supernatent prior to immunoprecipitation. 
 
3.7 Gene expression microarray assay 
 
RNA samples were isolated as described above (see 3.6) and RNA quality was 
measured by 2100 Bioanalyzer (Agilent Technologies, Santa Clara, Canada). Gene 
expression profile was performed in GeneChip Human Gene 1.0ST Array 
(Affymetrix, Santa Clara, Canada) by IZKF Aachen Chip Faculty, RWTH Aachen 
University Hospital, Aachen, Germany. Microarray data analysis was done in 
collaboration with Qiong Lin, Institute for Biomedical Engineering, Department of 
Cell Biology, RWTH Aachen University, Aachen, Germany. Raw microarray data 
were preprocessed and normalized by RMA algorithm implemented in Affymetrix 
Power Tools. The expression level of individual gene was calculated by averaging the 
signal intensities of all corresponding probesets. Hierarchical clustering analysis was 
performed using R. To gain functional insights, gene set enrichment analysis (GSEA) 
was conducted using pre-defined gene sets (ectoderm, mesoderm and endoderm) 
(Finger et al., 2011; Koch et al., 2009; Weidgang et al., 2013) and customized R script 
of GSEA. PluriTest and PhysioSpace analysis were done by Michael Lenz, Aachen 
Institute for Advanced Study in Computational Engineering Science, RWTH Aachen 
University, Aachen, Germany (Lenz et al., 2013; Muller et al., 2011). Data sets were 
submitted to Gene Expression Omnibus database (GEO; 
http://www.ncbi.nlm.nih.gov/geo) under accession number GSE58457.  
 
3.8 Immunofluorescence staining 
 
Cells were grown on gelatin-coated cover-slips, fixed with 4% paraformaldehyde (20 
min, RT) and permeabilized with PBS containing 0.1% Triton X-100 (Merck). Non-
specific binding was blocked with goat serum (Millipore, USA) for 30 min at RT. 
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Samples were then reacted with primary antibodies (12-16 hours, 4°C), washed twice 
with PBS and incubated with secondary antibodies (1 hour, RT). Samples were 
mounted with mounting solution (Dako, Denmark) on glass slides and images were 
acquired with Axiovert 200 microscope (Carl Zeiss, Germany). The following 
primary antibodies were used: OCT3/4 (1:50; Santa Cruz Biotechnology), SSEA-4 
(1:100), TRA-1-60 (1:100), NESTIN (1:200; all Millipore), cardiac troponin T (cTnT) 
(1:50), AFP (1:100), ALB (1:100; all R&D, Minneapolis, MN). Secondary antibodies 
were: anti-mouse/rabbit Alexa Fluor 594 (1:300, Invitrogen). Cell nuclei were stained 
with Hoechst 33258 (10 min, RT). 
 
3.9 Immunohistochemical staining 
 
EB or teratoma samples were fixed in 4% formaldehyde for 24 h at 4°C and 
embedded in paraffin. Paraffin embedded samples were sliced with a rotating 
microtome (Leica) at 3 mm thickness. Hematoxylin and eosin staining was performed 
according to routine histological protocols, in collaboration with Isabelle Leisten and 
Rebekka K. Schneider, Institute of Pathology, RWTH Aachen University Hospital, 
Aachen, Germany. An autostainer for immunohistochemistry (Dako cytomation) and 
the following primary antibodies were used: CD56 (also known as neural cell 
adhesion molecule, NCAM; 1:100), CD34 (1:25), AFP (1:1000; all Dako). Stained 
slides were dehydrated and mounted in Vitro-Clud (Langenbrinck, Emmendingen, 
Germany) 
 
3.10 Western blotting 
 
Protein samples (10 µg) were subjected to 8% polyacrylamide gel. Then proteins were 
transferred onto nitrocellulose membranes. Membranes were blocked with 5% non-fat 
milk in 0.1% Tween-20 Tris-Buffered Saline (T-TBS) for 1 hour at RT and incubated 
with anti-p-SMAD2 antibody (Ser465/467, 1:1000 dilution; Cell Signaling 
Technology, Beverly, MA) or anti-ACTIN antibody (Clone AC-74, 1:5000; Sigma-
Aldrich) overnight at 4°C. Membranes were washed with T-TBS for three times, 
incubated with peroxidase conjugated anti-rabbit or anti-mouse secondary antibody 
(NA934V and NA931, respectively; both 1:5000; GE Healthcare) for 1 hour at RT 
and washed three times with T-TBS. Bands were detected by chemiluminescence 
(ECL; Amersham Biosciences) and images were acquired by Image Reader Las-1000 
(Fujifilm) 
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3.11 Functional assays 
3.11.1 Colony forming unit assay (CFU assay) 
 
CFU assay was performed according to manufacturer’s instructions (Miltenyi Biotec). 
Briefly, EB of iPS hybrids and iPS cells (day 7) were dissociated with Trypsin 
treatment for 5 min and seeded into methylcellulose. After 6-10 days, colony 
morphology was observed by microscope.   	  
3.11.2 Low-density lipoprotein (LDL) uptake assay 
 
LDL uptake assay was performed according to manufacturer’s instructions (Abcam). 
Briefly, EB of iPS hybrids and iPS cells (day 7) were seeded into 96-well plates and 
continued culture for another 3-7 days. LDL-Dylight 594 (10 µg/ml; Abcam, 
Cambridge, UK) was added to the culture and incubated at 37°C for 4 hours. Cells 
were washed with culture medium three times, stained with Hoechst 33258 and 
observed by fluorescent microscope. 
 
3.11.3 Tube formation assay 
 
Endothelial cells can form tube like structure in Matrigel (Glaser et al., 2011). Tube 
formation assay is used to test such function in endothelial cells. Tube-formation 
assay was modified from Arnaoutova, I. et al (Arnaoutova and Kleinman, 2010). 
Briefly, differentiating EB (day 7) were seeded into 0.1% gelatin coated 6-well plates 
and cultured for another 2-3 days. Cells with endothelial cell morphology were 
observed on day 9-10. Cells were then harvested by trypsin treatment (1 min, 37°C) 
and passed through 70 µm cell strainer (BD Biosciences) to remove cell clumps. 
Single cells were seeded in Matrigel-coated 24-well plate (2x105 cells/well) in 
differentiation medium with 40 ng/ml VEGF (Peprotech, London, UK) and cultured 
for 24 hours. Tube-formation was observed by phase-contrast microscope.  
 
3.11.4 Periodic-acid Schiff (PAS) staining 
 
Human hepatocytes and muscle cells can synthesize glycogen and glycogen in cells 
can be measured by PAS staining (Kania et al., 2004). For PAS staining, cells were 
differentiated in EB and on 0.1% gelatin as above (see 3.2.6) and fixed with 4% 
paraformaldehyde for 15 min at RT (day 21). PAS staining was performed according 
to manufacturer’s instructions (Sigma-Aldrich). Briefly, fixed samples were treated 
with periodic acid solution (5 min, RT) and rinsed three times with water. Then 
Schiff’s reagent was added (15 min, RT) and samples were washed again three times 
with water. Cell nuclei were stained with Hematoxylin solution (1 min, RT), washed 
three times with water and photographed. 
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3.11.5 Urea assay 
 
Urea assay was performed according to the manufacturer’s instructions (BioVision 
Inc., San Francisco, USA). In brief, culture supernatant was harvested from iPS 
hybrids and iPS cells at various periods of time of differentiation (day 7, 14 and 21) 
and reaction products were measured by spectrophotometry (570 nm). 
 
3.12 Teratoma assay 
 
About 1-5x106 undifferentiated iPS, ES, hybrids were harvested by treatment with 
Collagenase IV (1 mg/mL, 40 min, 37°C, Invitrogen) and injected subcutaneously 
into NSG mice (age: 6-10 weeks). After 8 weeks, mice were sacrificed and tumors 
were subjected to further analysis (see 3.9). All experimental procedures involving 
animal work was approved by local authorities in compliance with the German animal 
protection law. 
 
3.13 Biomaterials preparation 
 
LR704S, LR706S and LR708 were provided as sterile powder (see 2.15) and 
produced as uniform sheets in the pelleting machine at DWI, RWTH Aachen 
University (in collaboration with Dr. Xiaomin Zhu), according to the protocol 
described by Hoß et al. (Hoss et al., 2013). Briefly, each biomaterial sheet was 
produced from granules (1.2 g). Granules were put in the center between two Teflon 
foil sheets and plated on the pelleting platform. The platform was heated to 200°C and 
1 ton pressure was applied on the Teflon foil sheets for 1 min to form biomaterial 
sheets. Biomaterial sheets were cut according to the size of tissue culture plate, 
sterilized with 70% EthOH and dried for experiment use.   
 
3.14 Statistics analysis 
 
All data were obtained from at least three independent experiments. Statistical 
analysis of the data was performed with unpaired Student’s t-test. P<0.05 was 
considered statistically significant. Data were shown as mean ± SD. 
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4 Results 
4.1 Generation of hybrids from human pluripotent stem cells and HSC 
 
To obtain hybrid cells, we isolated CD34+ HSC from cord blood samples and 
introduced the selection markers puro and eGFP by lentivirus infection. Then CD34+ 
HSC were fused with iPS or ES cells. After puromycin selection, hybrid clones were 
picked for further analysis (Fig. 4.1).  
 
Fig. 4.1. Schematic presentation of experiment settings. CD34+ HSC were isolated by 
MACS CD34 microbeads from cord blood samples. HSC were then introduced with selection 
markers puro and eGFP and fused with iPS or ES cells. Puromycin was applied to screen 
hybrid clones. 
 
4.1.1 Construction and testing of plasmid vector 
 
pFUGIEpuro vector contains the human ubiquitin C promoter (UbC) driving 
puromycin resistance gene expression (puro) and an internal ribosome entry site 
(IRES) for expression of enhanced green fluorescent protein (eGFP; Fig. 4.2A). The 
puromycin resistance gene with XbaI and BamHI sites (600 bp) was obtained from 
pMSCVpuro vector by PCR (Fig. 4.2B and C) and cloned into XbaI/BamHI sites of 
pFUGIE vector (see 3.1). Four pFUGIEpuro plasmid vectors with puro and eGFP 
were obtained (Fig. 4.2D and E).  
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Fig. 4.2 Vector construction. (A) Schematic representation of pMSCVpuro, pFUGIE and 
pFUGIEpuro. (B) Puro fragment with XbaI and BamHI sites was amplified from 
pMSCVpuro vector by PCR. (C) PCR amplification product of puro fragment. (D) 
pFUGIEpuro vector map with locations of XbaI, BamHI and ClaI sites. (E) Restriction 
enzyme digestion product (XbaI and ClaI) of four representative pFUGIEpuro clones and of 
pFUGIE vector control (after and before restriction enzyme treatment with XbaI and ClaI).  
 
To test the expression of the two selection markers in mammalian cells, lentivirus 
containing pFUGIEpuro vector was first produced in HEK293T cells and then used to 
infect new HEK293T cells. After transfection, eGFP+ HEK293T cells were observed 
by fluorescence microscopy and eGFP+ cell numbers increased with time (Fig. 4.3A), 
demonstrating that eGFP is expressed in mammalian cells. Three days after 
transfection, lentivirus was harvested and used to infect again HEK293T cells. 
Puromycin treatment (4 µg/mL) caused some cell death and the remaining culture was 
confluent with eGFP+ cells (Fig. 4.3B). This indicates that mammalian cells are 
successfully infected with lentivirus and both selection markers (puro and eGFP) are 
expressed in mammalian cells.  
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Fig. 4.3 Testing of pFUGIEpuro vector in HEK293T cells. (A) eGFP expression in 
transfected HEK293T cells (24, 48 and 72 hours after transfection). Scale bar: 100 µm. (B) 
eGFP expression in infected HEK293T cells 24 hours after puromycin selection. Scale bar: 
1000 µm 
 
4.1.2 Culture and infection of HSC 
 
CD34+ HSC (0.5x106 cells/umbilical sample) were isolated with MACS CD34 
microbeads kit and maintained in StemSpan medium supplemented with 100 ng/mL 
SCF, 50 ng/mL FLT-3 ligand, 20 ng/mL TPO and 10 ng/mL hyper-IL-6. During in 
vitro culture, HSC gradually progressed from stem cells (CD34+CD31+CD45-) 
towards progenitor cells (CD34-CD31-CD45+), as determined by FACS analysis of 
surface markers (Fig. 4.4).  
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Fig. 4.4 Expression kinetics of hematopietic surface markers during in vitro culture of 
HSC. FACS profiles represent surface marker changes of HSC isolated from cord blood 
during in vitro culture (day 0, 5 and 10 after isolation).  
 
The optimized transfection method of pFUGIEpuro vector in HEK293T cells 
yielded >90% of HEK293T cells expressing eGFP (Fig. 4.5A). High titer of lentivirus 
was collected and used to infect HSC (1-2x106 cells; 3 days after in vitro culture). 
More than 70% of HSC expressed eGFP after 48 hours of infection as determined by 
FACS (Fig. 4.5B-C). When applying puromycin (4 µg/mL, 24 hours), frequencies of 
eGFP+ HSC population were enriched up to 98% (Fig. 4.5C). Puromycin treatment 
was not applied to HSC before fusion, because of high cytotoxicity (data not shown). 
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Fig. 4.5 Lentivirus infection of HSC. (A) eGFP expression in HEK293T cells after 48 hours 
of transfection. Scale bar: 400 µm. (B) eGFP expression in HSC after 48 hours of infection. 
Scale bar: 200 µm. (C) Proportion of eGFP+ cells in HSC before and after puromycin 
selection (4 µg/mL, 24 hours).  
 
4.1.3 Culture of human iPS cells 
 
Human iPS cells, which were maintained under MEF culture condition, grow in 
compact colonies and showed high nucleus/cytoplasm ratio. Prior to cell fusion, iPS 
cells were switched to feeder-free culture condition in mTeSR1 medium to avoid 
contamination of hybrids with MEF cells. Growth morphology of iPS cells in both 
MEF and feeder-free culture condition were very similar (Fig. 4.6).  
 
 
Fig. 4.6 Phase contrast images of iPS cells (iLB30) under MEF and mTeSR1 culture 
condition. Scale bar: 200 µm.  
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4.1.4 Cell fusion 
 
Cell fusion was performed as described above (see 3.3). iPS cells (2x106) and HSC 
(4x106) were mixed as 1:2 and PEG was applied to obtain cell fusion. Unfused HSC 
(suspended cells) were removed from culture one day later by medium change. After 
puromycin treatment (4 µg/mL, 24 hours), iPS hybrid clones (efficiency: 1 
hybrid/1x105 cells) were recovered from single cells and picked one week later.  
 
4.2 Characterization of iPS hybrid clones 
4.2.1 Growth of iPS hybrids 
 
iPS hybrid clones were picked, 4 clones were expanded in MEF culture condition and 
finally 3 clones were investigated in detail. iPS hybrids showed similar growth 
morphology as parental iPS cells, only with double cell size (Fig. 4.7A). Every three 
days iPS hybrids were passaged on fresh MEF. iPS hybrids showed similar cell 
doubling time (about 24 h) as parental iPS cells (Fig. 4.7B). 
 
Fig. 4.7 Growth morphology and growth kinetics of iPS hybrids and iPS cells. (A) Phase 
contrast images of undifferentiated iPS hybrids and iPS cells grown on MEF feeder. Scale 
bar: 200 µm. (B) Growth kinetics of iPS hybrids and parental iPS cells. 
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4.2.2 iPS hybrids are tetraploid 
 
The chromosome number of iPS hybrids was determined by flow cytometry and M-
FISH analysis. Measured by flow cytometry, iPS hybrids showed 4n and 8n peaks (8n 
peak: representing of cell mitosis), whereas parental iPS cells showed 2n and 4n peaks 
(Fig. 4.8A). This indicates that hybrids are tetraploid (92 chromosomes). Additionally, 
iPS hybrids showed eGFP expression at a rather low level, which could be explained 
by IRES cassette (Bouabe et al., 2008). Previous studies reported that if two gene 
expressions were driven by the same promoter and connected by IRES cassette, the 
expression level of latter gene (after IRES cassette) is weaker compared to the gene 
before IRES cassette.  
 
To determine individual chromosome numbers, iPS hybrids and iPS cells were 
subjected to M-FISH analysis, by which each chromosome was distinguished by 
specific antibody and structure. As expected, iPS hybrids were defined as 4n 
(92,XXXY), compared with parental iPS cells (2n; 46,XY) (Fig. 4.8B). 
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Fig. 4.8 DNA contents of iPS hybrids and iPS cells. (A) DNA content measurement and 
eGFP expression by flow cytometry (red line: parental iPS cells; blue and green lines: iPS 
hybrids). (B) M-FISH analysis of iPS hybrids and iPS cells (in collaboration with Prof. Anna 
Jauch, Institute of Human Genetics, University Heidelberg, Heidelberg, Germany.). 
Hybrid_1-3 represented data from different hybrid clones. 
 
4.2.3 iPS hybrids show similar gene expression profile as parent iPS cells  
 
Global gene expression analysis showed that iPS hybrids were quite similar as 
parental iPS cells (Fig. 4.9A), including up-regulation of the pluripotency markers 
octamer-binding transcription factor 4 (OCT4) and NANOG and down-regulation of 
the hematopoietic markers CD34, CD45, runt-related transcription factor 1 (RUNX1) 
and so forth (Fig. 4.9B). Accordingly, OCT4 and NANOG promoter regions of iPS 
hybrids showed the enrichment of transcriptionally active mark H3K4me3, similar to 
parental iPS cells, as determined by ChIP-qPCR analysis (Fig. 4.9C). Hematopoietic 
lineage marker CD45 showed the H3K4me3 mark in HSC, which was lost in iPS 
hybrids. Confirmed by immunofluorescence staining, hybrids expressed the 
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pluripotency markers OCT4, stage-specific embryonic antigen-4 (SSEA4) and tumor 
rejection antigens 1-60 (TRA-1-60) similar to parental iPS cells (Fig. 4.9D).  
 
 
Fig. 4.9 Gene expression analysis of iPS hybrids under undifferentiated state. (A) Scatter 
plot analysis of global gene expression in undifferentiated iPS cells and iPS hybrids. (B) 
Bidirectional hierarchical cluster analysis of gene expression in HSC, undifferentiated iPS 
cells and iPS hybrids. (C) ChIP-qPCR analysis of H3K4me3 and H3K27me3 of OCT4, 
NANOG and CD45 promoters in undifferentiated cells. (D) Immunofluorescence staining of 
pluripotency markers in undifferentiated cells. Scale bar: 200 µm. 
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4.2.4 iPS hybrids show differentiation capacity towards three germ layers in vitro  
 
To characterize the in vitro differentiation capacity of iPS hybrids, cells were 
subjected to embryoid bodies (EB) assay (Fig. 4.10A). iPS hybrids formed EB in 
suspension culture (Fig. 4.10B).  
 
 
Fig. 4.10 In vitro differentiation of iPS hybrids. (A) Schematic representation of EB assay. 
iPS hybrids are grown on MEF feeder (undifferentiated cells, left) and subjected to EB assay 
in suspension culture (center) for 7 days. EB are seeded on gelatin coated dish for further 
differentiation (adherent culture, right). (B) Phase contrast images of EB (day 7). Scale bar: 
200 µm. 
 
At day 14 of differentiation, differentiated cells of iPS hybrids expressed lineage 
markers of three germ layers, including ectodermal markers NESTIN and beta-
Tubulin III (TUJ1), mesodermal markers α-myosin heavy chain (α-MHC) and cardiac 
troponin T (cTnT), endodermal markers α-fetoprotein (AFP) and albumin (ALB), as 
determined by immufluorescence staining (Fig. 4.11). This finding indicated that iPS 
hybrids acquire in vitro differentiation capacity of generating progenies of three germ 
layers, similar to parental iPS cells. 
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Fig. 4.11 Immunofluorescence staining of lineage markers (red) from three germ layers 
in differentiating iPS hybrids and parental iPS cells during EB assay (day 14). Blue, 
Hoechst staining of nuclei. Scale bar: 200 µm. 
 
4.2.5 iPS hybrids show three germ layer differentiation capacity in vivo 
 
The in vivo differentiation capacity of iPS hybrids was tested by teratoma assay. 
Undifferentiated iPS hybrids (1-5x106 cells) or iPS cells were injected subcutaneously 
into NSG mice (age: 8-12 weeks). After 8 weeks mice were sacrificed and tumors 
were removed for further analysis. From the gross morphology, tumors derived from 
iPS hybrids showed many cystic structures, compared to those from parental iPS cells 
(Fig. 4.12A). This is in consistent with cystic EB observed during in vitro 
differentiation of iPS hybrids (Fig. 4.10B). 
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Fig. 4.12. Teratoma assay of iPS hybrids and iPS cells. (A) Images of teratomas from iPS 
hybrids and parental iPS cells. (B) Hematoxylin and Eosin staining (HE staining) analysis of 
teratoma samples from iPS hybrids and parental iPS cells (ectoderm: neural epithelial tissue; 
mesoderm: cartilage tissue; endoderm: respiratory tissue). Scale bar: 200 µm. 
 
Determined by Hematoxylin and Eosin staining (HE staining), tissue types of three 
germ layers were identified in iPS hybrids, similar to parental iPS cells (Fig. 4.12B). 
These data indicate that hybrids can form teratoma in NSG mice and have the 
capacity to differentiate into three germ layers in vivo.  
 
Taken together, iPS hybrids are pluripotent, indicated by growth morphology, gene 
expression profile and three germ layer differentiation capacity both in vitro and in 
vivo. 
 
4.3 Mesendodermal differentiation bias of iPS hybrids  
 
Interestingly, in both in vitro and in vivo differentiation assays, we observed 
prominent cystic structures in iPS hybrids (Fig. 4.10B and Fig. 4.12A). Cystic 
structures are indicative of mesendodermal cells, such as hematopoietic cells, 
endothelial cells, cardiomyocytes and hepatocytes as shown before (Abe et al., 1996; 
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Chen et al., 1992; Doetschman et al., 1985; Kim et al., 2011; Peiffer et al., 2007; 
Risau et al., 1988; Wang et al., 1992). Therefore, we hypothesized that iPS hybrids 
exhibit a differentiation bias towards mesendoderm.  
 
4.3.1 iPS hybrids show differentiation bias during spontaneous differentiation  
 
Gene expression analysis of samples during spontaneous differentiation showed that 
indeed mesendodermal lineage markers were expressed at a higher level in iPS 
hybrids than parental iPS cells (Fig. 4.13A).  
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Fig. 4.13 Gene expression of differentiating iPS hybrids and iPS cells. (A) Hierarchical 
cluster analysis of gene expression in iPS hybrids and iPS cells during spontaneous 
differentiation. Data were displayed in heat map format. Hybrid_1-3 represented data from 
different cord blood samples. (B) Representative RT-qPCR analysis of gene expression during 
differentiation. Data are presented as mean ± SD of three independent experiments. (*p < 
0.05). 
 
Mesodermal markers, such as CD31, CD34, HCN4 and α-MHC, and endodermal 
markers ALB and PDX1 were abundantly expressed in hybrids, compared to parental 
iPS cells. Ectodermal markers, such as SRY-box containing gene 1 (SOX1) and 
microtubule-associated protein 2 (MAP2), were 3-4 fold less expressed in 
differentiating iPS hybrids than parental iPS cells control (Fig. 4.13A and Fig. 4.13B).  
 
Immunohistochemistry staining (IHC staining) analysis of EB sections (day 14 of 
spontaneous differentiation) showed prominent expression of mesendodermal lineage 
markers (CD34 and AFP) localized around cystic structures within EB of iPS hybrids, 
whereas neural lineage marker CD56 (also known as neural cell adhersion molecule, 
NCAM) was highly expressed in parental iPS cells (Fig. 4.14). 
 
Fig. 4.14 Immunohistochemical staining of EB sections (day 14). EB were fixed, 
embedded in paraffin and sectioned. Sections were subjected to immunohistochemistry 
staining with specific antibodies as indicated (brown). Counterstaining, HE (blue). Scale bar: 
200 µm. 
 
To further extend this analysis, we subjected iPS hybrids during spontaneous 
differentiation (day 0, 2, 4, 7 and 14) to global gene expression profiling. PluriTest 
analysis, which marks pluripotent cells (red, based on 98 pluripotent stem cell lines) 
and somatic cells (blue, based on 1028 somatic cell types) based on genome and/or 
epigenome of cells from different differentiation states (Muller et al., 2011; Willmann 
et al., 2013), provided the routes of iPS hybrids through reprogramming and 
differentiation (Fig. 4.15A). Upon cell fusion, the somatic genome in iPS hybrids was 
reprogrammed into a pluripotent state, resulting in high pluripootency score of iPS 
hybrids in pluripotent region (red). Interestingly, upon the onset of differentiation, 
such pluripotent iPS hybrids showed a faster differentiation kinetics than parental iPS 
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cells, switching from pluripotent region to somatic region (blue).  
 
Gene set enrichment analysis (GSEA) on germ layer specific transcription factors 
indicated that iPS hybrids were already biased to mesendodermal lineages at an early 
stage of differentiation (day 2 and 4; Fig. 4.15B). Such distinct differentiation bias of 
iPS hybrids was maintained along further differentiation, compared with parental iPS 
cells (day 7 and 14; Fig. 4.15C). Specifically, PhysioSpace analysis (Lenz et al., 2013) 
showed that iPS hybrids differentiated into a wide range of mesendodermal tissue 
types (heart, vascular tissues, reproductive system, mesenchymal tissues, lung, 
stomach, liver, spleen, kidney and intestine) but rather limited neural tissue types, in 
comparison with parental iPS cells (Fig.4.15D).  
 
 
Fig. 4.15 Gene expression microarray analysis of differentiating iPS hybrids and iPS 
cells. (A) PluriTest analysis of differentiating iPS hybrids and iPS cells. PluriTest is based on 
genomic and/or epigenomic analysis of cells from pluripotent state to differentiated state, and 
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marks region of pluripotent cells in red and region of somatic cells in blue. (B) Gene set 
enrichment analysis (GSEA) of differentiating iPS hybrids and iPS cells (day 2 and 4; P < 
0.0001). (C) Cluster analysis of transcriptomes of iPS hybrids and iPS cells during 
differentiation. (D) PhysioSpace analysis of differentiating iPS hybrids and iPS cells. 
PhysioSpace is generated from a database, which contains expression profiles of different 
somatic cells. Therefore, it provides information on somatic cell types of differentiating iPS 
hybrids and iPS cells.  
 
4.3.2 iPS hybrids give rise to progenies of mesendoderm with full cell function 
 
Characteristics of different tissue types (hematopoietic cells, endothelial cells, 
cardiomyocytes and hepatocytes), which were derived from iPS hybrids, were 
analyzed.  
 
Hematopoietic linage. iPS hybrids were subjected to hematopoietic differentiation 
with a modified differentiation protocol (Kennedy et al., 2012). Determined by colony 
forming unit assay (CFU assay), we showed that iPS hybrids generated both erythroid 
and myeloid colonies, whereas parental iPS cells can only give rise to erythroid 
colonies (Fig. 4.16A and B). Moreover, iPS hybrids differentiated further to 6-fold 
more CD11c+ dendritic cells (52%) than parental iPS cells (9%), which has been 
confirmed by RT-qPCR analysis (Fig. 4.16C and D). Taken together, we showed that 
hematopoietic differentiation efficiency is greatly enhanced in iPS hybrids, and iPS 
hybrids derived hematopoietic cells acquire differentiation potential towards erythroid 
and myeloid progenies. 
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Fig. 4.16 Functional analysis of hematopoietic cells derived from iPS hybrids and iPS 
cells. (A) Representative morphology colony forming units of erythrocytes (CFU-E), 
granulocytes (CFU-G) and granulocytes/macrophages (CFU-GM) from differentiating iPS 
hybrids, iPS cells and HSC control. N.D. indicates not detected. Scale bar: 200 µm. (B) 
Frequency of CFU types formed in differentiating iPS hybrids, iPS cells and HSC control. 
Mix colony contains erythroid cells and myeloid cells. Myeloid colony includes granulocytes 
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and macrophages. Data were collected from three independent experiments. (C) Flow 
cytometry of dendritic cells derived from iPS hybrids and iPS cells (day 21). (D) RT-qPCR 
analysis of hematopoietic gene expression of differentiating iPS hybrid and iPS cells (day 21). 
Data are presented as mean ± SD of three independent experiments, *P<0.05. 
 
Endothelial lineage. PhysioSpace analysis showed that iPS hybrids differentiated to 
many different types of vascular tissues, for instance, aorta, coronary artery and 
saphenous vein (Fig. 4.15D). Consistent with this result, large portion of cobblestone-
like endothelial cells appeared as monolayer from day 9 of iPS hybrid differentiation, 
and proliferated continuously to form vascular tube-like structure (day 14; Fig. 4.17). 
In adjacent to the endothelial cells were non-adherent cells (probably hematopoietic 
lineage cells) and beating areas (cardiomyocytes).  
 
 
Fig. 4.17 Phase contrast images of endothelial cells differentiated from iPS hybrids (day 
14). Scale bar: 200 µm. 
 
Low-density lipoprotein (LDL) receptor, which represents a receptor on the cell 
surface of endothelial cells and hepatocytes, is responsible for the uptake of LDL 
from the serum. We found that LDL from culture medium can be uptaken by the 
cobblestone-like monolayer cells derived from iPS hybrids (day 10), and such LDL 
uptake capacity was enhanced with time (day 14), whereas differentiating iPS cells 
used as a control showed no LDL uptake capacity (Fig. 4.18A). Specifically, cells that 
took up LDL located around vascular tube-like structure (Fig. 4.18B). To exclude the 
possibility that positive cells were hepatocytes, we performed immunofluorescence 
staining of hepatocyte marker (ALB). We showed that cells around the vascular tube-
like structure, which are positive for LDL uptake assay, did not express ALB (Fig. 
4.18C). Therefore, we conclude that the cells, which showed LDL uptake capacity 
around day 14 of differentiation, are endothelial cells. In other word, endothelial cells 
derived from iPS hybrids are capable of LDL uptake.  
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Fig. 4. 18 LDL assays of endothelial cells of differentiating iPS hybrids and iPS cells. (A) 
LDL uptake assay of endothelial cells differentiated from iPS hybrids and iPS cells (day 10 
and 14). Red indicates LDL uptake by cells. Blue, Hoechst staining of cell nuclei. (B) LDL 
uptake assay of endothelial cells differentiated from iPS hybrids with vascular tube-like 
structure (day 14). (C) ALB immunofluorescence staining of vascular tube-like structure in 
iPS hybrids. Scale bar: 200 µm. 
 
In addition to LDL uptake assay, we performed tube-formation assay to further 
analyze the function of endothelial cells. Endothelial cells form three-dimensional 
capillary-like structure in Matrigel-coated plate (de Groot et al., 1995). Normally, 
tube-formation assay was performed in homogeneous endothelial cell population 
(Arnaoutova and Kleinman, 2010; Choi et al., 2012). However, without enriching 
endothelial cells from culture, endothelial cells from iPS hybrids formed three-
dimensional tube-like structure, whereas cells of parental iPS cells did not form tube 
structures (Fig. 4.19). Taken together, iPS hybrids show enhanced differentiation 
towards functional endothelial cells, compared to parental iPS cells.  
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Fig. 4. 19 Tube formation assay of endothelial cells from differentiating iPS hybrids. 
Please note tube-like structures in differentiating iPS hybrids (day 10). iPS cells are shown as 
control. Scale bar: 200 µm. 
 
Cardiac lineage. Beating area is the direct indicator of functional cardiomyocyte 
derivation. During differentiation, beating areas in differentiating iPS hybrids 
appeared earlier and at higher frequencies, compared to parental iPS cells. The first 
beating area of differentiating iPS hybrids was observed at day 7 of differentiation and 
numbers of beating areas increased with time, while the first beating area of iPS cells 
was found at day 11 of differentiation and maximal 21 beating areas occurred during 
differentiation (Fig. 4.20A and B). With the same EB number seeded, there was a 
higher frequency of beating areas in iPS hybrids than in parental iPS cells (Fig. 
4.20C). These findings indicate that differentiation towards functional cardiac lineage 
is enhanced in iPS hybrids.  
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Fig. 4.20 Analysis of beating areas in differentiating iPS hybrids and iPS cells. (A) 
Numbers of beating areas occurring during spontaneous differentiation of differentiating iPS 
hybrids and iPS cells. (B) Representative images of beating areas in differentiating iPS 
hybrids and iPS cells (day 7 and 14 EB; day 14 adherent cells). White circles indicate beating 
areas. Magnification: 5x. (C) Analysis of cardiomyocyte differentiation efficiency of iPS 
hybrids (Hybrid_1 and 2) and iPS cells. Data are presented as mean ± SD of three 
independent experiments (t-test was calculated between iPS hybrid and parental iPS cells, *p 
< 0.05). 
 
Hepatic lineage. As for cells from endoderm, we analyzed the function of hepatocytes 
derived from iPS hybrids and iPS cells. Hepatocytes appeared as clusters with cubical 
morphology and frequently showed polyploid nuclei (day 21; Fig. 4.21A). Mature 
hepatocytes have many physiological functions, for instance, protein synthesis, lipid 
metabolism and detoxification. Here we measured the abilities of glycogen synthesis 
by Periodic-acid Schiff (PAS) staining and urea secretion (ammonia metabolism) by 
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urea assay. Hepatocytes derived from iPS hybrids showed a higher frequency of PAS 
positive cells and secreted urea at a higher level than parental iPS cells (Fig. 4.21B 
and C). In summary, more functional hepatocytes are derived from iPS hybrids than 
from iPS cells.  
 
Fig. 4.21 Functional assays of hepatocytes of differentiating iPS hybrids and iPS cells. 
(A) Phase contrast images of hepatocytes in iPS hybrids. (B) PAS staining (day 21) and (C) 
urea assay of hepatocytes derived from iPS hybrids and iPS cells (*p < 0.05). Scale bar: 200 
µm. 
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Collectively, we demonstrated that iPS hybrids show higher differentiation efficiency 
towards mesoderm and endoderm than parental iPS cells, and are able to generate 
functional differentiated cells.  
 
4.3.3 iPS hybrids retain mesendodermal differentiation bias during neural 
differentiation  
 
Culture conditions, which provide the external activators (e.g. growth factors of 
specific cell types), also play a role in directing in vitro differentiation capacity of 
pluripotent stem cells. Therefore we asked whether mesendodermal differentiation 
bias of iPS hybrids would change, when cells were subjected to culture conditions that 
favor neural differentiation.  
 
Fig. 4.22 Schematic representation of neural differentiation. iPS hybrids and parental iPS 
cells were maintained on MEF feeder (undifferentiated cells) and were subjected to EB assay 
in suspension culture for 7 days. EB were then seeded onto PL/LA coated dish (adherent 
culture) and cultured in neural differentiation medium with cytokines (bFGF and EGF) for 7 
days. Neural progenitors were further differentiated into mature cells in medium withdrawal 
of cytokines for another 7 days. SR: serum replacement; PO: Poly-orthinine; LA: Laminin. 
 
Neural differentiation was performed as described above (see 3.2.6; Fig. 4.22). 
Surprisingly, iPS hybrids maintained the differentiation bias towards mesendoderm 
even in neural differentiation medium. At day 21 of differentiation, parental iPS cells 
showed dominant structures of neuron axons and dendrites. In contrast, very few 
neural lineage cells were generated from iPS hybrids, whereas endothelial cells, 
hematopoietic cells and hepatocytes occurred at high frequency in culture (Fig. 
4.23A). The differentiation propensity of iPS hybrids towards mesendoderm was 
confirmed by gene expression analysis of three germ layer markers (Fig. 4.23B). 
These data suggests that external differentiation condition can not overcome the 
mesendoderm propensity of iPS hybrids.  
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Fig. 4.23 Mesendoderm differentiation propensity of iPS hybrids during neural 
differentiation. (A) Phase contrast images of differentiating iPS hybrids and iPS in neural 
differentiation medium (day 21). Scale bar: 1000 µm. (B) Bidirectional hierarchical cluster 
analysis of gene expression during neural specific differentiation. Data are presented as mean 
of three independent experiments. 
 
4.4 Towards elucidating the mechanisms of mesendodermal 
differentiation bias 	  
4.4.1 Enhanced primitive streak development in iPS hybrids during differentiation  
 
So far, we showed that iPS hybrids harbor mesendodermal differentiation bias and 
impaired neural differentiation capacity. To explode the underlying mechanism of 
differentiation bias of iPS hybrids, we shifted this observation window towards the 
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early differentiation phase (day 0 to 6), where the first lineage commitment decision 
towards ectoderm or mesendoderm is made.  
 
Primitive streak is the first structure for mesendodermal differentiation in embryo 
development (Mikawa et al., 2004; Tam and Loebel, 2007). We measured markers of 
primitive streak, including Brachyury (T), MIX1 Homeobox-Like Protein 1 (MIXL1) 
and Goosecoid (GSC), which are early transcription factors for mesendoderm 
commitment (Hirst et al., 2006; Murry and Keller, 2008).  
 
Fig. 4.24 Expression kinetics of early transcription factors of cell fate commitment in 
differentiating iPS hybrids and iPS cells. (A) Expression kinetics of T, MIXL1 and GSC in 
differentiating iPS hybrids and parental iPS cells. Samples were generated from EB assay 
(day 0, 2, 4 and 6) during spontaneous differentiation. Gene expression at day 0 was 
arbitrarily set 1. Data are presented as mean ± SD of three independent experiments, *P<0.05. 
(B) Hierarchical cluster analysis of early developmental markers from primitive streak to 
further lineage commitment (Meso/Endoderm and Ectoderm) in differentiating iPS hybrids 
and iPS cells. 
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iPS hybrids expressed all these markers at higher levels than parental iPS cells with a 
prominent peak at day 2 (Fig. 4.24A). An overview of early transcription factor 
expression related to cell fate commitment is displayed in a heat map (Fig. 4.24B). 
iPS hybrids committed to mesendoderm from day 2 of differentiation, as shown by 
high expression of the primitive streak markers T, MIXL1, GSC and EOMES.  
 
Following the expression of these primitive streak markers, early transcription factors 
targeting specific meso/endodermal lineages (cardiac lineage: MESP1; hemangioblast 
cells: FLK1; definitive endoderm: FOXA2 and SOX17) were up-regulated in 
differentiating iPS hybrids (Bondue et al., 2008; Wu, 2008; Wu et al., 2008). 
Moreover, early ectodermal transcription factors were expressed at rather low levels 
in iPS hybrids, which is in sharp contrast of parental iPS cells.  
 
Additionally, these expression data correlated well with an enrichment of 
transcriptionally active mark H3K4me3 at the T, MIXL1 and GSC promoters at day 2 
of iPS hybrid differentiation (Fig. 4.25A). In parental iPS cells, there was an 
enrichment of transcriptionally repressive mark H3K27me3 of relative primitive steak 
markers (Fig. 4.25B).  
 
Collectively, primitive streak development is effectively enhanced of iPS hybrids 
during early differentiation, resulting in better mesendodermal differentiation of iPS 
hybrids, compared with parental iPS cells. 
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Fig. 4.25 ChIP-qPCR analysis of H3K4me3 and H3K27me3 in T, MIXL1, GSC and 
OCT4 promoter regions of differentiating iPS hybrids (A) and iPS cells (B). Samples 
were generated from EB assay as described in Fig. 4.24A. Data are presented as mean ± SD 
of three independent experiments.  
 
4.4.2 Enriched NODAL signaling directs mesendodermal differentiation bias of 
iPS hybrids.  
 
NODAL, WNT3 and BMP4 are key signal pathways involved in regulating early 
germ layer specification, specifically directing primitive streak formation and further 
differentiation towards to mesoderm and endoderm (Nostro et al., 2008). We found 
that all three genes were highly up-regulated in iPS hybrids compared to parental iPS 
cell during early phase of differentiation (Fig. 4.26). However, only the expression 
kinetics of NODAL was closely related to that of primitive markers (T, MIXL1 and 
GSC) in iPS hybrids, which peaked at day 2 of differentiation. NODAL is essential in 
regulating primitive streak formation and mesendoderm differentiation (Massague and 
Xi, 2012; Tam and Loebel, 2007; Xi et al., 2011). Addition of recombinant NODAL 
protein to differentiation medium of human ES cells resulted in more cystic EB 
formation in culture (Vallier et al., 2004). As a result, we focused on elucidating the 
role of NODAL signaling in mesendodermal differentiation bias of iPS hybrids.  
 
Fig. 4.26 Expression kinetics of NODAL, WNT3 and BMP4 in early differentiating iPS 
hybrids and iPS cells. Samples were generated as described in Fig. 4.24A. Data are 
presented as mean ± SD of three independent experiments. Gene expression at day 0 was 
arbitrarily set 1. *P<0.05, **P<0.01. 
 
Consistent with gene expression analysis, we found an enrichment of transcriptionally 
active mark H3K4me3 at the NODAL promoter in differentiating iPS hybrids at day 2 
compared to parental iPS cell control (Fig. 4.27A). 
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Fig. 4.27 Analysis of NODAL signaling by ChIP-qPCR and Western blotting. (A) ChIP-
qPCR analysis of H3K4me3 and H3K27me3 kinetics in NODAL promoter region of 
differentiating iPS hybrids and iPS cells as in Fig. 4.25. (B) Western blot analysis of p-
SMAD2 in differentiating iPS hybrid and iPS cells. 
 
Phosphorylated-SMAD2 (p-SMAD2), which is the down-stream protein of NODAL 
signaling also occurred with accelerated kinetics at day 2 in iPS hybrids compared to 
parental iPS cell control, as determined by Western blotting (Fig. 4.27B). Collectively, 
we conclude that NODAL signaling, which is a key component in mesendodermal 
commitment, is highly activated at an early stage of iPS hybrid differentiation. 
 
4.4.3 Mesendodermal differentiation bias of iPS hybrids is blunted by inhibiting 
NODAL signaling 
 
To test the notion that NODAL is directly involved in the mesendodermal 
differentiation propensity in iPS hybrids, we applied SB431542 (SB) to block 
NODAL/SMAD signaling (Inman et al., 2002).  
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Fig. 4.28 Inhibition of NODAL signaling in differentiating iPS hybrids by SB treatment. 
(A) Western blotting analysis of p-SMAD2 with or without SB (EB assay, day 2, 20% FCS). 
(B) Phase contrast images of EB during spontaneous differentiation of iPS hybrids with or 
without SB. Scale bar: 200 µm. (C) Analysis of cystic EB frequency in iPS hybrid 
differentiation culture with and without SB treatment (day 7; **P=0.0003). 
 
As shown by Western blotting, SB efficiently inhibited NODAL signaling, as 
demonstrated by decreased protein level of p-SMAD2 (Fig. 4.28A). Consistently, with 
SB treatment occurrence of cystic EB was greatly reduced in differentiating iPS 
hybrids (Fig. 4.28B, C). 
 
Upon SB treatment, expression of primitive streak markers and mesodermal lineage 
markers was down-regulated in iPS hybrids accordingly, while ectodermal marker 
expression was up-regulated (Fig. 4.29A, B). This indicates that the mesendodermal 
differentiation propensity of iPS hybrids shifted towards ectoderm, When NODAL 
signaling was inhibited in iPS hybrids.   
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Fig. 4.29 Gene expression analysis of differentiating iPS hybrids. (A) Expression kinetics 
of T, MIXL1 and GSC during spontaneous differentiation (day 0, 2, 4 and 6) of iPS hybrid 
with or without SB treatment. Gene expression at day 0 was arbitrarily set 1. Data are 
presented as mean ± SD of three independent experiments, *P<0.05. (B) Bidirectional 
hierarchical cluster analysis of gene expression during spontaneous differentiation with or 
without SB treatment as in (A). 
 
Furthermore, to avoid the influence of signaling activators in serum, we analyzed 
differentiation capacity of iPS hybrid with SB treatment in neural differentiation 
medium (serum-free). Previous results showed that iPS hybrids still showed 
mesendodermal differentiation propensity during neural differentiation (Fig. 4.23). 
However, after 7 days of suspension culture with SB treatment, no cystic EB were 
observed in differentiating iPS hybrids (Fig. 4.30A). In later phase of differentiation 
	  	  	   72	  
with SB, more neural precursors were obtained in differentiating iPS hybrids, 
compared to solvent control (data not shown). Gene expression analysis (day 21) 
showed that all neural lineage markers, including markers of neural progenitor, 
neurons, astrocytes and oligodendrocytes, were highly expressed in iPS hybrids with 
SB treatment, whereas mesendodermal markers were less expressed compared to 
solvent control (Fig. 4.30B).  
 
 
Fig. 4.30 Analysis of iPS hybrids during neural differentiation with or without SB. (A) 
Phase contrast images of EB derived from iPS hybrids with or without SB treatment (day 7). 
Scale bar: 200 µm. (B) Hierarchical cluster analysis of gene expression upon neural 
differentiation with or without SB (serum-free condition) as in (A). 
 
Collectively, inhibiting NODAL signaling by SB blocks the differerntiation bias of 
iPS hybrids towards mesendoderm. Taken together, these findings suggest that the 
active NODAL/SMAD signaling pathway is essential to mesendodermal 
differentiation propensity of iPS hybrids. 
 
4.5 iPS hybrids derived from other iPS cells also show mesendodermal 
differentiation bias 
 
To test whether the mesendodermal differentiation propensity of iPS hybrids exists in 
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other iPS hybrids, we used another iPS cell line (iPS_2) for fusion with HSC. iPS_2 
hybrid clones were generated and 2 clones were investigated further. iPS_2 hybrids 
showed similar growth morphology as parental iPS cells (Fig. 4.31A). iPS_2 hybrids 
were tetraploid and expressed eGFP as shown by flow cytometry analysis (Fig. 
4.31B). Undifferentiated iPS_2 hybrids showed similar gene expression profile as 
parental iPS_2 cells, up-regulation of pluripotency markers and down-regulation of 
HSC lineage markers (Fig. 4.31C), indicating that upon fusion somatic genome in 
iPS_2 hybrids was reprogrammed into a pluripotent state.  
 
Fig. 4.31 Characterization of iPS_2 hybrids from iPS_2 and HSC. (A) Phase contrast 
images of undifferentiated iPS_2 hybrids and iPS_2. Scale bar: 1000 µm. (B) Flow cytometry 
analysis of DNA contents and eGFP expression in iPS_2 hybrids and parental iPS_2 cells (red 
line: iPS_2 cells; blue and green lines: iPS_2 hybrids). (C) Bidirectional hierarchical cluster 
analysis of gene expression in HSC, undifferentiated iPS_2 cells and iPS_2 hybrids. Hybrid_4 
and 5 represented data from different cord blood samples.  
 
When undifferentiated cells of iPS_2 hybrids were injected subcutaneously into NSG 
mice, cystic teratoma was also generated 8 weeks later and within the tumor there 
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were tissue types from three germ layers (Fig. 4.32A, B). 
 
 
 
Fig. 4.32 Teratoma assay of iPS_2 hybrids and iPS_2 cells. (A) Images of teratomas from 
iPS_2 hybrids and iPS_2 cells. (B) HE staining of tissue types from three germ layers in 
teratomas (ectoderm: neural epithelial tissue; mesoderm: cartilage tissue; endoderm: glandular 
epithelium). Scale bar: 200 µm. 
 
During in vitro differentiation, we also observed many cystic EB in suspension culture 
of iPS_2 hybrids (Fig. 4.33A). Moreover, gene expression analysis of spontaneous 
differentiation showed mesendodermal differentiation propensity of iPS_2 hybrids 
and such bias remained under neural specific differentiation (Fig. 4.33B, C).  
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Fig. 4.33 Mesendodermal differentiation propensity of iPS_2 hybrids. (A) Phase contrast 
images of EB (day 7) of iPS_2 hybrids and parental iPS_2 cells. Scale bar: 200 µm. (B) and 
(C) Hierarchical cluster analysis of gene expression in iPS_2 hybrid_5 and iPS_2 cells during 
spontaneous differentiation and neural differentiation, respectively. 
 
Prominent expression of primitive markers and p-SMAD2 was also observed in iPS_2 
hybrids derived from iPS_2 cells, with peaks at day 4 (Fig. 4.34A, B).  
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Fig. 4.34 Expression of primitive streak markers and NODAL signaling in 
differentiating iPS_2 hybrids and iPS_2. (A) Expression of T, MIXL1 and GSC in 
differentiating iPS_2 hybrid_5 and iPS_2 cells (day 0, 2, 4 and 6). Gene expression at day 0 
was arbitrarily set 1. Data are presented as mean ± SD of three independent experiments,  
*P<0.05. (B) Western blot analysis of p-SMAD2 in differentiating iPS_2 hybrid_5 and iPS_2 
cells as in (A). 
 
Moreover when applying SB in serum-free differentiation conditions, mesendodermal 
differentiation bias of iPS_2 hybrids was also blocked (Fig. 4.35). These findings 
indicate that the differentiation propensity of iPS hybrids towards mesendoderm is 
independent of HSC preparations and iPS cell lines. 
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Fig. 4.35 Bidirectional hierarchical cluster analysis of gene expression in iPS_2 hybrid_5 
during neural differentiation with or without SB inhibitor. iPS_2 hybrid_5 and iPS_2 
cells were subjected to neural differentiation (serum-free) with or without SB treatment as in 
Fig. 4.30.  
 
4.6 Hybrids derived from human ES cells and HSC show 
differentiation bias. 
 
As a further control, ES hybrids were generated from human ES cell line H9 and 
HSC. ES hybrid clones were picked and expanded in MEF culture condition. Finally, 
3 ES hybrid clones were further analyzed (Fig. 4.36A, B).  
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Fig. 4.36 Growth morphology and DNA content analysis of ES hybrids and parental ES 
cells. (A) Phase contrast images of undifferentiated ES hybrids and ES cells grown on MEF 
feeder. Scale bar: 200 µm. (B) Flow cytometry analysis of DNA contents and eGFP 
expression in ES hybrids and parental ES cells (red line, ES cells; blue line, ES hybrids). 
 
ES hybrids expressed pluripotency markers OCT4, SSEA4 and TRA-1-60, as 
determined by immunofluorescence staining (Fig. 4.37).  
 
Fig. 4.37. Immunofluorescence staining of pluripotency markers in undifferentiated ES 
hybrids and ES cells. Undifferentiated ES hybrids and ES cells were stained for pluripotency 
markers OCT4, SSEA4 and TRA-1-60. Scale bar: 200 µm.   
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Additionally, undifferentiated ES hybrids generated teratomas in NSG mice. In 
accordance with other iPS hybrids, cystic structures were found in ES hybrids (Fig. 
4.38A). Additionally, we confirmed that tissue types of three germ layers were formed 
within the tumors, indicating that ES hybrids can differentiate into three germ layers 
in vivo (Fig. 4.38B).
 
 
Fig. 4.38 Teratoma assay of ES hybrids and ES cells. (A) Teratomas of ES hybrids and ES 
cells. (B) HE staining of teratoma samples. Tissue types of three germ layers were found 
(ectoderm: neural epithelial tissue; mesoderm: cartilage tissue; endoderm: glandular 
epithelium). Scale bar: 200 µm.   
 
During EB assay, cystic EB were appeared in both differentiating ES hybrids and ES 
cells (Fig.4.39A). There was no significant differences of mesendodermal 
differentiation between ES hybrids and ES cells, only impaired neural differentiation 
of ES hybrids was observed by gene expression analysis during differentiation (Fig. 
4.39B).  
 
	  	  	   80	  
 
 
Fig. 4.39 In vitro differentiation capacity of ES hybrids and ES cells. (A) Phase contrast 
images of EB in differentiating ES hybrids and ES cells (day 7). Scale bar: 200 µm. (B) 
Bidirectional hierarchical cluster analysis of gene expression in ES hybrids and ES cells 
during spontaneous differentiation (day 7 and 14). Hybrid_6-8 represented different ES 
hybrid clones from different cord bloods. 
 
In accordance with gene expression of three germ layers in ES hybrids, there was no 
large difference of primitive streak marker expression during early differentiation 
between hybrids and parental ES cells. Only MIXL1 and GSC expression in 
differentiating ES hybrids was higher than parental ES cells (Fig. 4.40).  
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Fig. 4.40 Primitive marker expression of differentiating ES Hybird and ES cells. ES 
hybrids and parental ES cells were subjected to spontaneous differentiation and primitive 
marker expression was analyzed (day 0-6).  
 
We also investigated the expression of key signal pathways for mesendodermal 
differentiation in both ES hybrids and ES cells. Similar as iPS hybrids, ES hybrids 
expressed higher level of NODAL than parental pluripotent stem cells, which 
correlated with higher levels of MIXL1, GSC expression and impaired neural 
differentiation (Fig. 4.41).  
 
Fig. 4.41 NODAL, WNT3 and BMP4 expression in differentiating ES hybrids and ES 
cells. Spontaneous differentiation was performed as described in Fig. 4.40 and the expression 
of NODAL, WNT3 and BMP4 genes was measured by RT-qPCR. 
 
Collectively, ES hybrids showed cystic structures in teratomas, impaired neural 
differentiation and activated NODAL signaling during early differentiation phase. 
Based on these data, we expected to see mesendodermal differentiation bias of ES 
hybrids, as in iPS hybrids. However, such bias was not observed in spontaneous 
differentiation condition (containing serum). One explanation is that ES cells have 
unbiased or more balanced three germ layer differentiation capacity than iPS cells. 
Serum contains many activators of NODAL/BMP4/WNT3 signalings regulating 
mesendoderm differentiation and ES cells showed similar mesendodermal 
differentiation capacity as ES hybrids. We assumed that if ES hybrids still harbor 
mesendodermal differentiation propensity, such phenomenon should be observed 
under neural specific differentiation condition (serum free), where mesendodermal 
activators are removed and ES cells readily differentiate into ectoderm.  
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As expected, prominent mesendodermal differentiation propensity of ES hybrids was 
observed under neural differentiation condition (Fig. 4.42), indicating that like other 
iPS hybrids, the ES hybrids also have the differentiation bias towards mesendoderm. 
 
Fig. 4.42 Bidirectional hierarchical cluster analysis of gene expression in ES hybrids and 
ES cells during neural differentiation (day 14 and 21). ES hybrids and ES cells were 
subjected to neural differentiation (serum free; as described in 3.2.6 and Fig. 4.22) and 
analyzed for germ layer marker expression.  
 
4.7 Fusion of human iPS cells with other somatic cells 
 
Differentiation bias was observed in all the iPS hybrids derived from iPS cells and 
HSC fusion. To test whether such differentiation bias varies according to different 
somatic fusion partner, we performed fusion experiment by using iPS cells and other 
somatic cell types, human mesenchymal stem cells (hMSC) or human fibroblasts 
(hFi)(both were derived from healthy donors and were kindly provided by Hatim 
Hemeda and Prof. Wolfgang Wagner, Helmholtz Institute for Biomedical 
Engineering, Stem Cell Biology and Cellular Engineering, RWTH Aachen University, 
Aachen, Germany).  
 
Since both fusion partners (iPS and hMSC/hFi) are adherent cells in culture, we had 
to apply further advanced selection strategies, such as double antibiotic selection (Fig. 
4.43A) or single antibiotic combined with morphology selection (Fig. 4.43B). 
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Fig. 4.43 Experiment designs of fusion with two adherent cell types. (A) Experiment 
design of double antibiotic selection. In this selection system, each fusion partner harbars one 
antibiotic resistance gene (hygromycin B or purymycin) introduced by retrovirus. After 48 
hours of fusion, antibiotics were applied (hygromycin B: 50-300 µg/mL; puromycin: 4-8 
µg/mL) for 24 hours. (B) Experiment design of single antibiotic combined with morphology 
selection. Somatic fusion partner was infected by lentivirus to introduce one antibiotic 
resistance gene. After fusion with PEG, antibiotic treatment was applied. Then hybrid clones 
were picked based on pluripotent cell morphology.  
 
However, no hybrid clones was obtained from neither of the experimental setup. In 
double antibiotic selection setting, cells did not survive after double antibiotics 
selection, regardless of low/high antibiotics concentration or sequential/simultaneous 
selection (data not shown). The approach of single antibiotic combined with 
morphology selection, we found rather low cell viability of somatic fusion partner 
after lentivirus infection, leading to no hybrid clones later. In addition, we found that 
hMSC were more difficult to infect compared with hFi (Fig. 4.44).  
  
Fig. 4.44 Images of hMSC and hFi after lentivirus infection. hMSC and hFi were infected 
by puro-eGFP lentivirus and culture images (left panel, phase contrast images; right panel, 
fluorescence images) were taken 48 hours after infection. Upper panel: hMSC; lower panel: 
hFi. Scale bar: 1000 µm. 
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Therefore, we chose hFi as somatic fusion partner, infected with retrovirus, applied 
single antibiotic selection and picked hybrid colonies based on pluripotent 
morphology (Fig. 4.45A). In this modified fusion strategy, we obtained two hybrid 
clones. Shown by flow cytometry, hybrids were tetraploid with 4n and 8n peaks (Fig. 
4.45B). Additionally, hybrids expressed pluripotency markers, as determined by 
immunofluorescence staining (Fig. 4.45C). These data indicate that hybrids from 
different somatic fusion partner show similar characteristics in undifferentiated state. 
Surprisingly, as these hybrids would not proliferate to passage 2 and thus prevented 
their further analysis. Poor cell proliferation rate is also indicated in DNA content 
measurement by flow cytometry, where hybrids showed rather small 8n peak (Fig. 
4.45B). Poor cell viability of hybrids can be the result of virus infection, PEG 
treatment and antibiotic selection, all of which load survival pressure on somatic 
fusion partner and later on hybrids.  
 
Fig. 4.45 Characterization of hybrids from iPS and hFi cells. (A) Experiment design of 
fusion between iPS and hFi cells. (B) Flow cytometry analysis of DNA content of hybrids 
from iPS and hFi. (C) Immunofluorescence staining of pluripotency markers of hybrids 
cultured on MEF feeder (red: OCT; green: TRA-1-60) in hybrids. Scale bar: 200 µm. 
 
4.8 4n-2n transition 
 
Previous result from mouse ES cell fusion with Flt3+ bone marrow cells showed that 
hybrids transit from 4n to 2n cells upon in vitro differentiation and also in teratoma 
assay. To check whether such 4n-2n transition exists in human hybrids, we measured 
the DNA content of iPS hybrids after 60 days of in vitro differentiation. However, we 
did not observe transition in human hybrids (Fig. 4.46). iPS hybrids remained 4n/8n, 
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although the 8n peak was much lower than 4n peak, indicating cell cycle arrest when 
cells undergo terminal differentiation. Human ES hybrids also showed stable 4n DNA 
content during in vitro differentiation (data not shown). 
 
Fig. 4.46 Flow cytometry analysis of DNA content and eGFP expression of differentiated 
iPS hybrids and parental iPS cells. iPS hybrids and parental iPS cells were subjected to 
spontaneous differentiation as described in 3.2.6 and Fig. 4.10. Only the differentiation 
culture was proloned up to 60 days and DNA content and eGFP expression were then 
measured by flow cytometry (red line: iPS cells; blue line: iPS hybrids). 
 
Additionally, we also checked the exogenous gene existence (eGFP and puro), which 
are integrated in the somatic genome, in iPS hybrids. Shown by qPCR analysis of 
eGFP and puro genes in DNA samples isolated from teratomas (undifferentiated cells 
as control), we found similar copy number of eGFP and puro genes between teratoma 
samples and undifferentiated iPS hybrids (Fig. 4.47), suggesting that iPS hybrids still 
contain the somatic genome after a period of in vivo differentiation. This finding 
indicates that the 4n-2n transition does not exist in human hybrids during in vivo 
differentiation.  
 
Fig. 4.47 qPCR analysis of eGFP and puro gene in DNA samples from teratomas (ter) 
and undifferentiated iPS hybrids. Undifferentiated iPS hybrids and parental iPS cells were 
injected subcutaneously into NSG mice as described in 3.12. NSG mice were sacrificed 8 
weeks later and teratomas were obtained. DNA was isolated from teratomas and investigated 
via qPCR the copy number of eGFP and puro genes integrated in the somatic genome. 
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4.9 Cardiomyocyte differentiation of human iPS cells on biomaterials 
 
Previous study demonstrated that biomaterial LR704, chemical name Poly(L-lactide-
co-D,L-lactide), promotes cardiomyocyte differentiation from mouse germline 
derived pluripotent stem cells (gPS cells)(Hoss et al., 2013). Here, serial of these 
biomaterials were tested in human iPS cells. Differentiation of iPS cells was 
performed as described above (see 3.2.6). Briefly, EB (day 7) were plated onto 0.1% 
gelatin coated biomaterials (LR704S, LR706S and LR708) or tissue culture plastic 
(TCP, as control), and continued culture for another 14 days (Fig. 4.48A). Numbers of 
beating areas with biomaterials (0-3 beating areas/10 cm2 culture area) was less than 
those of TCP (10-21 beating areas/10 cm2 culture area). Lineage specific marker 
expression (day 21) analysis showed that differentiated cells on biomaterials were 
similar to those on TCP (Fig. 4.48B). Expression of early and late cardiomyocyte 
markers (NKX2.5 and α-MHC, respectively) was at least 2-fold higher on TCP than on 
biomaterials. These data indicate that biomaterials can not enhance the human iPS cell 
differentiation towards neuron, cardiomyocte and hepatocyte lineages.  
 
Fig. 4.48 Differentiation analysis of iPS cells on biomaterials (day 21). (A) Experiment 
design of iPS cell differentiation on biomaterials. (B) Analysis of lineage specific marker 
expression of iPS cell differentiation on biomaterials. Gene expression at day 0 was arbitrarily 
set 1. Ectoderm: NF; Endoderm: ALB; Mesoderm (cardiomyocytes): NKX2.5, α-MHC. TCP: 
tissue culture plastic. Data are presented as mean ± SD of three independent experiments (*p 
< 0.05). 
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Additionally, we observed that the biomaterials had the surface topology of the Teflon 
foil used for printing, which might influence adherence and differentiation of iPS cells 
(Fig. 4.49).  
 
 
Fig. 4.49 Phase contrast images of adherent EB on biomaterials. iPS cells were 
differentiated as described above and culture images of adherent EB were taken (day 14). 
Scale bar: 200 µm. Arrow: surface structure of Teflon.  
 
To address this problem, we tried to replace Teflon by Aluminum matrix, which has 
smooth surface, in collaborations with Department of Macromolecular Chemistry and 
Fraunhofer Institute for Production Technology, IPT, Aachen, Germany. However, the 
smooth surface of Aluminum matrix was destroyed every time by granules of 
biomaterials, when 1 ton of pressure was placed on. Moreover, due to the viscosity of 
the biomaterials, biomaterial sheets were difficult to peal off from the Aluminum 
matrix. Thus, technological difficulties led us to terminate this project. 
 
4.10 Cardiomyocyte differentiation of human iPS cells by using small 
molecule  
 
The compound EBIO supports derivation of pacemaker cells from mouse ES cells 
(Kleger et al., 2010). In this study, we applied EBIO in human iPS cell differentiation. 
To determine the suitable working concentration of small molecule EBIO, we applied 
series dilution of EBIO in human iPS under growth condition (1:10 dilution factor, 
DMSO as solvent control). After 4 days of culture, we found that iPS clones died 
completely in 10 mM EBIO group, whereas cells survived at 0.01-1 mM 
concentration (Fig. 4.50A). Pluripotency marker OCT4 expression of iPS cells was 
down-regulated in a dose-dependent manner (Fig. 4.50B). Given that iPS cells in 1 
mM EBIO treatment group also eventually died in culture (data not shown), we used 
0.1 mM EBIO in differentiation experiments. When applying 0.1 mM EBIO for 7 
days, there was no significant cell death in EB suspension culture (Fig. 4.50C). 
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Fig. 4.50 EBIO titration and EB assay. (A) Phase contrast images of human iPS cell culture 
in different concentrations of EBIO (day 4). Scale bar: 200 µm. (B) OCT4 expression of 
human iPS cells in different EBIO concentrations (day 4). RNA from 10 mM EBIO group 
was not obtained due to cell death. (C) Phase contrast images of EB with and without EBIO 
treatment (0.1 mM, day 7) in EB assay. Scale bar: 1000 µm. 
 
EBIO (0.1 mM) was added to differentiation culture at different time points as 
outlined in Fig. 4.51 (Fig. 4.51). RNA was collected and analyzed by RT-qPCR.  
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Fig. 4.51 Experimental design of spontaneous differentiation with EBIO (0.1 mM). 
Group A: EBIO was added to the medium during the entire differentiation assay; Group B: 
EBIO was added to the medium during the early phase of differentiation (day 0-7); Group C: 
EBIO was added to the medium during the late phase of differentiation (day 7-14); Group D: 
EBIO was not added to the medium during the entire differentiation period (solvent control).  
 
During the culture, beating areas were observed in Group C and D. Accordingly, 
cardiomyocyte marker expression was higher in Group C and D (Fig. 4.52A). 
Apparently, cardiomyocyte differentiation was not improved with the treatment of 
EBIO, as the solvent control showed the best cardiomyocyte differentiation efficiency.  
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Fig. 4.52 Gene expression analysis of human iPS cells during differentiation with and 
without EBIO treatment. (A) Analysis of cardiomyocytes marker expression during 
differentiation (day 7 and 14) with and without EBIO treatment. (B) Analysis of early three 
germ layer differentiation marker expression during differentiation (day 7) with and without 
EBIO treatment. Ectoderm: SOX1; Mesoderm: TBX3; Endoderm: SOX17.  
 
Interestingly, when we analyzed the three germ layer marker expression in the early 
phase of differentiation, we found that EBIO enhanced ectodermal differentiation of 
human iPS cells (Fig. 4.52B).   
 
It is known that neural differentiation generates three different types of progenies: 
oligodendrocyte, astrocytes and neurons. We asked whether the effect of EBIO is 
specific to one neural lineage or to all the three neural lineages? We applied EBIO 
(0.1 mM) in neural differentiation assay. We found that EBIO treatment improved the 
differentiation to all the three neural lineages (day 14, Fig. 4.53).  
 
Fig. 4.53 Neural lineage gene expression analysis of hiPS cells during neural 
differentiation with and without EBIO treatment. iPS cells were subjected to neural 
differentiation as described in 3.2.6 with and without EBIO. Neural specific marker 
expression was analyzed in differentiated cells (day 14). O1: oligodendrocyte marker; GFAP: 
astrocyte marker; MAP2: neuron marker. 
 
Given that EBIO functions through activating SKCas channels (SK1-4), we wanted to 
know which SKCas channel is specifically activated by EBIO in human iPS cells, and 
responsible for iPS cell differentiation towards neural lineages. We analyzed the 
expression kinetics of SK1-4 genes with or without EBIO treatment during the 
differentiation. We found that SK1-4 gene expression showed different kinetics, and 
upon EBIO treatment all of the SK1-4 genes were 2-fold up-regulated at day 4 of 
differentiation (Fig. 4.54). In addition, even though the expression of SK3 and SK4 
were higher than SK1-2 in this iPS cells, due to the difference of primer pairs, it is 
difficult to compare the expression level among different SK genes. Therefore, at this 
stage of analysis, we can not conclude that the ectoderm differentiation promoting 
effect of EBIO is resulted from the activation of any one of SKCas subtypes. 
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Fig. 4.54 Analysis of SKs expression upon EBIO treatment during EB differentiation. 
iPS cells were subjected to neural differentiation as described in 3.2.6 with and without EBIO. 
RNA was isolated from differentiated cells (day 0, 2, 4 and 6) and analyzed for SK1-4 
expression. 
 
Next, we investigated whether such ectoderm differentiation effect of EBIO in human 
iPS cells is cell line dependent or not. We applied EBIO in spontaneous differentiation 
culture to another human iPS cell line (M4C4 human iPS cells derived from human 
mesenchymal stem cells, in collaboration with Prof. Wolfgang Wagner, Helmholtz 
Institute for Biomedical Engineering, Stem Cell Biology and Cellular Engineering, 
RWTH Aachen University, Aachen, Germany. and Prof. Tomo Saric, Institute for 
Neurophysiology, University of Cologne School of Medicine, Germany). To our 
surprise, EBIO showed no impact on M4C4 iPS cell differentiation, neither to 
ectoderm nor to mesoderm (Fig. 4.56).    
 
Fig. 4.56 Analysis of early three germ layer differentiation in M4C4 human iPS cells 
with and without EBIO treatment. M4C4 human iPS cells were subjected to spontaneous 
differentiation as described in 3.2.6 with and without EBIO. RNA was isolated during 
differentiation (day 0, 2, 4 and 6) and analyzed for three germ layer marker expression. 
Ectoderm: PAX6; Mesoderm: TBX3; Endoderm: SOX17.  
 
Taken together, we show that EBIO down-regulates pluripotency marker expression 
of human iPS cells in a dose-dependent manner. Additionally, the effect of EBIO on 
differentiation appears to be unspecific and dependent on the iPS cell lines used.  
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5 Discussion  
 
In this study, we demonstrate that iPS hybrids with HSC show mesendodermal 
differentiation bias. Such iPS hybrids harbor enhanced differentiation capacity 
towards the hematopoietic lineage and also towards other mesendodermal lineages 
(endothelium, cardiomyocytes and hepatocytes). Additionally, during differentiation 
of iPS hybrids expression of early mesendodermal markers appeared with a faster 
kinetics than in parental iPS cells. Following iPS hybrid differentiation there was a 
prominent induction of NODAL and inhibition of NODAL signaling blunted 
mesendodermal differentiation. This indicates that NODAL signaling is critically 
involved in mesendodermal bias of iPS hybrid differentiation (Fig. 5.1). 
 
 
Figure 5.1 Main findings of differentiation study of iPS hybrids. Shortly after cell fusion, 
somatic genome was reprogrammed into a pluripotent state. Interestingly, iPS hybrids showed 
a differentiation bias towards mesendoderm. Such bias was driven by enhanced NODAL 
signaling. 
 
5.1 Factors determining fusion efficiency  
 
There are three critical elements determining cell fusion efficiency – cell viability, cell 
types and fusion methods.  
 
Cell viability is the primary element to affect fusion efficiency. First of all, a certain 
cell number is required for both fusion partners based on PEG fusion method. The 
fusion efficiency of human samples is about 1x10-5 (0.001%) (Yu et al., 2006). In our 
experiment settings, at least 1x106 cells for each fusion partner are needed for fusion. 
Cells with good viability are easy to reach that cell number for fusion. Another aspect 
is that good cell viability drives cell division after cell fusion, which can speed up the 
reprogramming process and reach cell stability (Han et al., 2008). The formation of a 
single nucleus marks the completion of reprogramming, which requires DNA 
synthesis and mitosis (Lee et al., 2009; Tsubouchi et al., 2013). Hybrids which failed 
to undergo DNA synthesis and mitosis, would maintained as heterokaryons and die 
later on (Bhutani et al., 2010; Han et al., 2008; Tsubouchi et al., 2013). For primary 
cells (e.g. HSC or MSC), it is quite difficult to maintain good cell viability during in 
vitro culture. Lentivirus infection and antibiotics selection load extra survival 
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pressures on these primary cells. Frequently we observed cell differentiation and cell 
death in HSC culture after virus infection, especially under high titer virus infection. 
Such challenge is even obvious in infected fibroblasts and MSC, where cells almost 
stopped proliferation after virus infection.  
 
Cell types also influence the fusion efficiency. Cells differ in cell size, which 
determines the ratio of cell numbers between two fusion partners. Since fusion event 
happens randomly by using PEG method, to ensure the contact of both fusion partners 
with equal chance, cell size and cell ratio must be taken into consideration. Here, we 
used 1:2 ratio of iPS/ES cells to HSC for fusion. Even though the average cell sizes of 
iPS/ES and HSC are similar (around 10 µm), but after 7-10 days of in vitro culture as 
well as virus infection, a fraction of HSC started to differentiate and had enlarged cell 
size. Besides, somatic cells have different kinetics of in vitro aging, which affects 
fusion efficiency (Tat et al., 2011). In this study, we obtained higher fusion efficiency 
with HSC than with fibroblasts or MSC.  
 
Three approaches are commonly used to fuse cells, including PEG (Pontecorvo, 
1975), electrofusion and Hemagglutinating virus of Japan envelop (HVJ-E; Sendai 
virus) (Kaneda et al., 2002) (Table 5.1).     
 
Table 5.1 Comparison of different fusion approaches. 
 PEG Electrofusion HVJ-E 
Fusion efficiency 
(human cells) 
low (<1x10-5) 
(Yu et al., 
2006) 
high (80-fold higher 
than PEG) (Neil and 
Zimmermann, 1993) 
high (5-9x10-5) 
(Hasegawa et 
al., 2010) 
Required cell number 1x106 2x105 1x105 
Cell toxicity high low low 
 
PEG is a polyether component with a basic chemical formular as HO(CH2CH2O)nH. 
PEG, which has molecular weight between 400-6000 in concentration range of 50-
55%, could be used as a fusion reagent (Davidson et al., 1976). However, detailed 
mechanism of PEG fusion is poorly understood. Several studies indicated that PEG 
acts as a dehydration reagent that brings adjacent cell membranes to molecular 
contact. Then by the influence of additives in the commercial PEG, the outer and the 
inner leaflet lipids of cells are mixed sequentially, and small fusion pores are formed 
to make the fusion complete (Lentz and Lee, 1999; Wojcieszyn et al., 1983). Although 
PEG is widely used in cell fusion, it has some drawbacks. Frequently, giant 
polykaryons are formed in PEG based method, due to the randomness of fusion event. 
Cell death is often observed because of cell toxicity of PEG, hence a higher cell 
number for fusion (1x106 cells) is required. In addition, there is no universal protocol 
for PEG fusion. Fusion protocol should be adjusted according to different cell types 
with distinct size and shape, and the optimal fusion efficiency varies among different 
molecular weight of PEG. 
 
Compared to PEG, electrofusion works in a much more controllable way. Cells are 
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first brought together to a close membrane contact by dielectrophoresis in a weak 
inhomogeneous alternating current (AC) field; then cell membranes breakdown into 
small reversible pores by a very short-field pulse of high intensity and cell fusion 
occurs (Vienken et al., 1983). The fusion process can be observed directly under the 
microscope and small cell number of fusion partners is needed. Moreover, fusion 
efficiency is quite high (Sukhorukov et al., 2006), regardless of the cell types used 
(Neil and Zimmermann, 1993). The only disadvantage of electrofusion is the 
requirement of fusion equipment (Radomska and Eckhardt, 1995).  
 
HVJ-E is a component of Sendai virus, which can assist the penetration of cell 
membranes. HVJ-E contains two types of proteins, HN protein and F protein. HN 
protein has hemagglutinating and neuraminidase activities, which can bind to its 
receptor in cell membrane. F protein is responsible for lipid intermixings and fusion 
(Maeda et al., 1977). There is a commercial kit for cell fusion, named GenomONETM-
CF EX (Ishihara Sangyo, Osaka, Japan, http://www.iskweb.co.jp/hvj-e). The fusion 
process by HVJ-E includes three steps: first, HVJ-E binds to its receptors (acetyl type 
sialic acid recognized by HN protein) on the cell surface at 0-8°C; then the 
hydrophobic domain of F protein of HVJ-E penetrates into the liquid layer of cell 
membrane, leading to close contact of two cell membranes; last, at 37°C the 
hydrophobic connection force is enhanced and cell fusion takes place. This fusion 
approach has lower cell toxicity and higher fusion efficiency than PEG fusion. 1x105 
cells would be sufficient to make fusion experiment. Given the known fusion 
mechanism and protocol, it is easy to manipulate and reproduce, regardless of cell 
types (e.g. suspension/adherent cells and cell size). So far, HVJ-E has been applied in 
many fusion studies, including human zygotes, human fibroblasts and human ES cells 
(Craven et al., 2010; Hasegawa et al., 2010).  
 
5.2 Reprogramming of somatic genome in hybrids into a pluripotent 
state. 
 
Fusion between two cells at different differentiation states shows that less 
differentiated cells are dominant over more differentiated cells (Hochedlinger and 
Jaenisch, 2006) (Fig. 5.2). In cell fusion between pluripotent stem cells and somatic 
cells, the somatic fusion partner is reprogrammed into a pluripotent state. Hybrids, 
derived from somatic-multipotent stem cell fusion, acquire multipotency relevant to 
its multipotent fusion partner. For instance, fusion study between human fibroblasts 
and human CD34+ hematopoietic precursors, showed that the hybrids had 
hematopoietic precursors-like morphology and can differentiate into hematopoietic 
progenies (Sandler et al., 2011). However, such reprogramming process does not 
happen in somatic-somatic cell fusion, where somatic cells mostly maintain their own 
cell identity but express some genes activated by transcription factors in other somatic 
fusion partner (Foshay et al., 2012).  
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Fig. 5.2 Fusion between cells at differential differentiation states give rise to different 
phenotypes of hybrids. When a pluripotent stem cell was fused with a somatic cell, the 
somatic genome is reprogrammed into a pluripotent state. When a multipotent stem cell was 
fused with a somatic cell, the somatic genome is reprogrammed into a multipotent state. 
When two somatic cells were fused together, somatic cell identity remains and no 
reprogramming occurs. 
 
What is the rationale behind this phenomenon? Trans-acting factors, which come from 
intracellular transcription factors of fusion partners and external culture condition, 
provide some explanations.  
 
As known, trans-acting factors (i.e. factors that bind to gene regulatory sequences to 
promote or repress gene expression) and cis-acting factors (i.e. DNA and chromatin 
structures that regulate gene expression, such as DNA methylation) interact with each 
other to regulate gene expression (Lahn, 2011). One scenario about the interaction 
between trans-acting and cis-acting factors suggests that trans-acting factors act as an 
upstream event to cis-acting factors in regulating gene expression. That is 
transcription factors bind to gene regulatory region, then recruit chromatin marks 
either to repress or activate gene expression. iPS generation serves as an example. The 
reprogramming of a somatic cell can be initiated by ectopic expression of 4 
transcription factors, and later the pluripotency landscape is established epigenetically 
(Muraro et al., 2013).  
 
Different fusion partners contain distinct repertoire of intracellular transcription 
factors and contribute to the transcription milieu of hybrids, altering the phenotype of 
the hybrids. Findings of fusion between different cell combinations (i.e. somatic-
pluripotent stem cell; somatic-multipotent stem cells; somatic-somatic) suggest a 
hierarchy of transcription factors within cells of different differentiation states 
(pluripotent > multipotent > somatic cell). Therefore, the transcriptional network in 
hybrids is dominated of less differentiated cells (Fig. 5.3). 
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Fig. 5.3 Hierarchy scheme of transcriptional networks in cells at different differentiated 
states. Based on phenotype studies of hybrids from cell fusion, a hypothesis about the 
transcription factors can be drawn out. There is a hierarchy among the transcription factor 
repertoires of pluripotent stem cells, multipotent stem cells and somatic cells. Less 
differentiated cells dominate over more differentiated cells.  
 
In somatic-somatic cell fusion, although no reprogramming event occurs, gene 
expression profile of one fusion partner is changed to some extent, according to 
intracellular transcription milieu of the other fusion cell partner. When diverse human 
somatic responder cells were fused with mouse muscle cells (mesoderm), activation 
of muscle specific gene (NCAM) was observed to different extends in responder cells, 
keratinocytes (ectoderm; 60%), fibroblast (mesoderm; 95%) and hepatocytes 
(endoderm; 25%), respectively (Blau and Blakely, 1999). This result again supports 
that transcription factor set of the fusion partner is very crucial for determining the 
phenotype of hybrids.    
 
Apart from the intracellular transcription factors, the culture condition of cells after 
fusion also plays a role in modifying the hybrid phenotype. Culture condition 
provides external growth factors that favor the gene expression of certain cell types. 
So far, hybrids were cultured in medium of one fusion partner (muscle cells, 
hematopoietic stem cells or ES cells), and showed the phenotype of the relevant 
fusion partner. It is of interest to supply hybrids with culture medium of the other 
somatic fusion partner, and to see whether such hybrids would show different 
phenotype. If so, the impact of culture medium on the phenotype determination of 
hybrids should be reassessed. 
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5.3 Mesendodermal differentiation bias of hybrids  
 
In this study, the hybrids can differentiate into three germ layers, but they showed 
different differentiation bias, compared to parental pluripotent stem cells. 
Neuroectoderm differentiation has been shown to be the “default” pathway of in vitro 
differentiation of human pluripotent stem cells (Munoz-Sanjuan and Brivanlou, 2002; 
Smukler et al., 2006). However, upon cell fusion of human pluripotent stem cells with 
HSC, hybrids showed mesendoderm differentiation bias (see 4.3). They possess 
enhanced differentiation capacity not only towards HSC lineage, but also towards 
other mesendoderm (cardiac, endothelial and hepatocyte) lineages.  
 
5.3.1 NODAL signaling pathway is closely related to mesendodermal 
differentiation propensity of hybrids 
 
It is known that the mesoderm and endoderm development originates from primitive 
streak, and this process is regulated by NODAL, WNT3, BMP4 and FGF signaling 
pathways (Murry and Keller, 2008; Rossant and Tam, 2004; Tam and Loebel, 2007). 
Among these signaling pathways, NODAL serves as a major regulation factor in 
primitive streak formation and mesendoderm development (Murry and Keller, 2008; 
Tam and Loebel, 2007; Xi et al., 2011).  
 
During gastrulation, NODAL is expressed throughout the primitive streak (Varlet et 
al., 1997). When adding recombinant NODAL into differentiation medium of human 
ES cells, cystic EB were induced, which was significantly different from compact EB 
morphology in the control group (Vallier et al., 2004). NODAL knockout mouse 
epiblasts give rise to mainly neuroepithelial cells and no mesendodermal lineages, 
during in vitro differentiation (Camus et al., 2006).  
 
Cystic EB and cystic teratomas appeared constantly during in vitro and in vivo 
differentiation of hybrids (see 4.3). In hybrids generated from either iPS or H9 ES 
cells, NODAL signaling was consistently differentially expressed between hybrids 
and parental pluripotent stem cells (see 4.4.2). Accordingly, primitive streak marker 
expression was prominently up-regulated in hybrids, resulting in enhanced 
mesodermal and endodermal differentiation efficiency. Moreover, when applying 
NODAL signaling inhibitor in the differentiation culture, differentiation bias of iPS 
hybrids was shifted from mesendoderm to neuroectoderm. Taken together, NODAL 
signaling is the major trigger of directing mesendodermal differentiation bias of 
hybrids.  
 
5.3.2 Differentiation variations among hybrids from different HSC preparation, 
human iPS cell line and human ES cells 
 
Although the mesendodermal differentiation bias is consistent in all the hybrids, we 
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observed some variations among the hybrids generated from different HSC 
preparations, iPS cell lines and human H9 ES cells. For instance, hybrids from 
different HSC preparation showed different differentiation preference of mesodermal 
progenies. iPS hybrid_2 gave rise to more cardiomyocytes than iPS hybrid_1 (Fig. 
4.20C). In addition, hybrids derived from different iPS cells displayed with different 
developmental kinetics. When primitive streak marker expression peaked at day 2 of 
iPS hybrid_1-3 differentiation, those markers were highly expressed at day 4 of iPS_2 
hybrids differentiation. Different from iPS hybrids, ES hybrids showed similar 
mesendodermal differentiation ability as parental ES cells during spontaneous 
differentiation.  
 
All the clonal differentiation variations can be attributed to different regulation 
networks of NODAL, WNT3 and BMP4 signalings during early germ layer 
specification. WNT3 expression was prominently up-regulated during early 
differentiation of iPS hybrid_2 (data not shown), which show good cardiac 
differentiation. iPS_2 hybrids, which displayed a slow primitive streak development 
wave, showed lower expression of WNT3 and BMP4 than iPS hybrid_1-3. WNT3 
and BMP4 expression level were quite similar in ES hybrids and parental ES cells, 
leading to similar mesendodermal differentiation efficiency. As a result, we assumed 
that the clonal differences in hybrids result from different spatially and temporally 
interaction of NODAL signaling with other signaling pathways. 
 
We then asked what controls the differential activation of NODAL, WNT3 and BMP4 
signalings in hybrids? By the time of in vitro differentiation, two genomes within the 
hybrids already mix well and hybrids of different cell origins share the same culture 
medium.  
 
Fig. 5.4 Possible mechanisms of clonal variations in mesendodermal differentiation of 
hybrids. Each fusion partner is different, although they are defined as one specific cell 
category, such as HSC or iPS cells. This variation results in the clonal differences in 
differentiation propensity of hybrids.  
 
Hence, it is likely that hybrids differ in the accessibility of gene regulatory region (i.e. 
cis-acting factors or epigenetic landscape). For example, when hybrids have different 
DNA methylation around development related genes or tissue specific genes, it would 
	  	  	   99	  
lead to differential susceptibility of activated factors upon differentiation. Such variant 
cis-acting factors might originate from the fusion partners (Fig. 5.4). 
 
Even though the HSC population has been selected by using CD34 magnetic beads, 
CD34 marker is not exclusive for HSC lineages and after MACS selection 0.5% of 
the cells are still CD34 negative. Moreover after 10 days in vitro culture and virus 
infection, HSC gradually lose stemness and differentiate into progenitor cells or even 
committed to certain hematopoietic lineages, giving rise to a more diverse cell 
population. In order to restrict the somatic fusion partner to CD34+ category, we 
enriched CD34+ HSC by performing another selection with CD34 magnetic beads 
right before cell fusion. We obtained only one hybrid clone in this attempt, which 
might be due to very few CD34+ cells (0.8x106 cells) and poor cell viability after 
MACS selection. As a result, different HSC fusion partners (from hematopoietic stem 
cells to lineage committed cells) might influence in each fusion event.      
 
Pluripotent stem cells are also heterogeneous. Recent investigations on genetic and 
epigenetic variations in pluripotent stem cells (ES and iPS cells) showed that there are 
considerable differences among different iPS cell lines and between ES and iPS cells 
(Cahan and Daley, 2013) (Table 5.2).  
 
Table 5.2 Variations among pluripotent stem cell lines (Cahan and Daley, 2013). 
 
 
Differences among iPS cell lines, resulted from incomplete reprogramming/somatic 
memory or mutations occurred during reprogramming process, are correlated with 
differentiation propensity in vitro (Bock et al., 2011; Kim et al., 2010; Lister et al., 
2011; Polo et al., 2010) (Fig. 5.5). Some iPS cells have neural ectoderm priming, 
while others show differentiation propensity towards mesendoderm (Bock et al., 2011; 
Narsinh et al., 2011; Polo et al., 2010; Xu et al., 2012). The two iPS cell lines used in 
this study were derived from different methods (retrovirus or Sendai virus vectors) at 
different passage numbers (P50 vs. P15), and showed neuroectoderm differentiation 
bias.  
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Fig. 5.5 Possible reasons for in vitro differentiation bias of iPS cells. Somatic cell types 
(e.g. peripheral blood and fibroblast), donor cell age (young and old) and derivation methods 
(e.g. virus and virus free reprogramming methods) lead to different reprogramming kinetics of 
somatic cells into iPS cells. Any remnants of somatic genome (i.e. incomplete reprogramming 
or somatic memory) or mutations during reprogramming cause genetic and epigenetic 
differences of iPS cells. These in turn affect differentiation property of iPS cells and 
differentiation bias of iPS cells occurs. 
 
ES cells also differ from iPS cells. ES cells are derived from ICM of the blastocyst, 
while iPS cells are derived from different somatic cell types with divergent donor cell 
age and by different derivation methods. Thus, there are various parameters that can 
affect differentiation propensity. One study compared differentiation capacity of 3 
well-established human ES cell lines (H7, H9 and HES2) and four human iPS cells 
(Narsinh et al., 2011). They showed that iPS cells generate less functional 
cardiomyocytes and endothelial cells than ES cells. Single cell transcriptional profile 
indicated that positional variations in three germ layers already existed in 
undifferentiated iPS cells (neural ectoderm priming in peripheral region), but not in 
ES cells (Narsinh et al., 2011). Accordingly, the different mesendodermal propensity 
of iPS hybrids and ES hybrids could be explained by differences between ES and iPS 
cells.  
 
Cell fusion brings the content of the two cells together. The interaction of 
transcription factors from both fusion partners determines the new epigenetic 
landscape of the resulting hybrids. Under growth condition the pluripotency network 
dominants the transcriptional activity of hybrids. Upon differentiation, distinct 
epigenetic pattern in hybrids shows temporally different combination of signal 
pathways, responding to external activators and regulating the onset of germ layer 
specification. 
 
	  	  	   101	  
5.4 What causes mesendodermal differentiation bias of hybrids, 
somatic memory of HSC or distinct trait of tetraploid cells? 
 
Hybrids contain two sets of chromosomes, one from somatic cells and the other from 
pluripotent stem cells. We asked whether the mesendodermal differentiation bias 
originates from the somatic fusion partner?  
 
Partial reprogramming or somatic memory of the somatic fusion partner – HSC is one 
possible reason. Although pluripotent stem cells have the capacity to reprogram the 
somatic genome, it is unknown whether such reprogramming could reach 100% 
efficiency. The non-reprogrammed genome of HSC fusion partner may still function 
and lead to the bias (Fig. 5.6). HSC develop from pluripotent stem cells to mesoderm. 
As a result, it is reasonable to suspect that some residual memory of HSC drives 
hybrids to mesendoderm commitment. However, we could not find supportive 
evidence from our experiment data. 
 
Fig. 5.6 Model for partial reprogramming of hybrids. HSC are multipotent stem cells 
(grey) and iPS cells are pluripotent stem cells (black stripes). It is possible that some remnants 
of HSC genome remain in iPS hybrids, while the majority of HSC genome is reprogrammed 
into a pluripotent state after cell fusion.   
 
Somatic memory as remnants of the somatic cell has been described in iPS cells (Ohi 
et al., 2011; Polo et al., 2010). Somatic memory causes a differentiation bias towards 
lineages of the somatic cells used for reprogramming (somatic origin; Fig. 5.4). In 
addition, epigenetic evidence of somatic memory can be found in undifferentiated iPS 
cells and with continuous passaging the somatic memory of iPS cells will be erased 
(Hussein et al., 2011; Polo et al., 2010).  
 
Differentiation bias of hybrids shows different characteristics from the somatic 
memory of iPS cells. First, hybrids showed the differentiation bias towards a broad 
range of cell types, including hematopoietic cells (somatic cell type used for 
reprogramming) and also other cell types from the mesendoderm. When somatic 
memory of HSC fusion partner causes the bias, we should only observe enhanced 
differentiation towards hematopoietic lineage. Therefore, such broad range of 
differentiated cell types of hybrids does not support the somatic memory hypothesis. 
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Second, we did not find epigenetic evidence for somatic memory in hybrids. Shortly 
after cell fusion, hybrids already showed similar gene expression profiles as parental 
iPS cells. In addition, hybrids showed similar epigenetic profiles of hematopoietic and 
pluripotency genes as parental iPS cells. Furthermore, the mesendodermal 
differentiation bias in hybrids persisted at least until passage 34-40, whereas the 
somatic memory of iPS cells vanishes with higher passage numbers (passage >12) 
(Hussein et al., 2011). Finally, HSC do not express NODAL, which is the main trigger 
of the mesendodermal differentiation bias of iPS hybrids. As a result, the 
mesendodermal differentiation bias of hybrids can not simply be explained by 
remnants of the HSC fusion partner.  
 
Of note, we cannot exclude the possibility that other unknown somatic memory 
factors, which are not detectable or silent in pluripotent state but occur upon 
differentiation, contributes to the differentiation bias of hybrids (Cahan and Daley, 
2013). Such unknown factor causes differential susceptibility to differentiation 
signals. In our case, hybrids are more sensitive to NODAL signaling than parental iPS 
cells (Fig. 5.7). Once NODAL signaling is active, it would activate positive feedback 
to up-regulate the expression of itself on one hand and repress neural ectoderm 
differentiation on the other hand, resulting in mesendodermal differentiation bias.  
 
Fig. 5.7 Model of differential susceptibility of NODAL signaling in hybrids and parental 
pluripotent stem cells during differentiation. The unknown somatic memory in hybrids, 
which is not detectable under growth condition, causes higher susceptibility of differentiation 
signaling (e.g. NODAL) than parental pluripotent stem cells during differentiation.  
 
Or alternatively is the mesendodermal differentiation bias a distinct phenomenon of 
tetraploid cells? In previous studies, three germ layer differentiation capacity of 
hybrids has been documented, in order to confirm the pluripotency of the hybrids 
(Cowan et al., 2005; Do and Scholer, 2006; Tada et al., 2001). However the 
differentiation capacity to individual germ layer has not yet been compared. Some 
studies applied specific differentiation towards neural lineage and/or hepatocytes 
(Ying et al., 2002; Yu et al., 2006), which would enhance the differentiation efficiency 
to relevant germ layer, but makes it difficult to compare the three germ layer 
differentiation propensity. Interestingly, one study applied mouse hybrids (ES-neural 
cell) in chimera assay and showed that 4n hybrids integrated into limited germ layers 
(intestinal epithelial cells, heart and mainly liver) (Ying et al., 2002). Such limited 
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integration of tetraploid cells in the chimeric animals was explained by the growth 
disadvantage of 4n hybrids to 2n cells during development (Nagy et al., 1990). 
However, this study by Nagy et al. was based on a model, where tetraploid cells were 
generated from fusion of two totipotent stem cells at 2-cell stage. Whether the 
tetraploid cells from two totipotent stem cells (totipotent hybrids) share the same 
phenotype as those from ES-somatic cell fusion (pluripotent hybrids) is worth 
discussing (see below). Even though there is a competitive growth pressure on 4n 
cells in the presence of 2n cells, it is reasonable to assume that the remaining organ 
contribution of hybrids is resulted from the differentiation bias of hybrids. In this 
case, hybrids give rise to more cell types of certain germ layers, which are still 
traceable under the growth pressure of 2n cells along development in the chimeric 
embryos. 
 
Further experiments are needed to address the question, whether the differentiation 
bias is due to partial reprogramming/somatic memory of somatic cells or distinct 
characteristic of pluripotent hybrids. One approach is to use cell types from different 
species, for example, human and monkey cells for fusion. In this setting, the 
epigenetic signatures of the fusion partners are traceable. During differentiation, 
lineage commitment signals derived from each fusion partner are distinguishable. The 
other approach is to perform cell fusion of pluripotent stem cells with different 
somatic cells from ectoderm. If ectodermal differentiation bias occurrs, upon fusion of 
iPS cell with ectodermal somatic cell, then we could conclude that the differentiation 
bias is due to somatic memory. Vice versa, if the mesendodermal differentiation 
propensity of hybrids remained, we would conclude that it is the distinct character of 
pluripotent hybrids.     
 
5.5 Are they the same, totipotent hybrids and pluripotent hybrids? 
 
Totipotent hybrids are derived from two totipotent stem cells at 2-cell stage. Most 
homogeneous totipotent hybrids develop further until blastocyst stage, then abort 
spontaneously (Eakin et al., 2005; Kaufman, 1992; Kaufman and Webb, 1990; Snow, 
1975). There are a few totipotent hybrids, which could develop to full term, both in 
mouse and human (Eakin et al., 2005; Snow, 1975). In chimera assay extraembryonic 
tissues are dominated by totipotent hybrids; whereas 2n pluripotent stem cells 
developed into embryo (Eakin and Behringer, 2003; Nagy et al., 1990). Based on such 
special phenomenon, totipotent hybrids are used in tetraploid complementation assay 
to characterize the pluripotency of ES or iPS cells, where 2n pluripotent stem cells are 
injected into the blastocyst developed from totipotent hybrids. However, several 
studies reported that totipotent hybrids could also be found in some tissues of the 
embyo (heart, blood, liver, lung, kidney and intestinal epithelium) (Eakin and 
Behringer, 2003; Eakin et al., 2005; Goto et al., 2002; Wang et al., 1997). 
 
Compared with totipotent hybrids, derivation of pluripotent hybrids from ES-somatic 
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cell fusion involves reprogramming process from somatic cells. When somatic fusion 
partner is reprogrammed into a pluripotent state, the resulting hybrids acquire 
pluripotency, bearing the potential of three germ layer differentiation as totipotent 
hybrids. In chimera assay of pluripotent hybrids, they showed limited organ 
integration in chimeric embryos (intestinal epithelial cells, heart and mainly liver) 
(Ying et al., 2002), just like totipotent hybrids. Theoretically, totipotent stem cells (not 
pluripotent stem cells) acquire the potential to differentiate towards trophectoderm, 
which further develop into extraembryonic tissue - placenta. However, both totipotent 
and pluripotent hybrids show the extraembryonic tissue contribution in chimera assay, 
only to different extent (totipotent hybrids > 50%; pluripotent hybrids > 20%) (Do et 
al., 2011; Nagy et al., 1990). Therefore, both hybrids share similar capability in 
embryonic and extraembryonic tissue development. 
 
Another interesting question is why tetraploid cells mainly contribute to the 
extraembryonic tissues in chimera assay and tetraploid complementation assay? The 
mechanism for this phenomenon is largely unknown. (i) Totipotent stem cells differ 
from pluripotent stem cells in the extraembryonic tissue development. (ii) ES cells or 
iPS cells can not develop into extraembryonic tissues (Do et al., 2011). (iii) When 
combined with 2n pluripotent stem cells in chimera assay, totipotent hybrids show 
differentiation preference to extraembryonic tissues. These observations suggest that 
totipotent hybrids gain more developmental potential than ES or iPS cells. Chimeric 
embryo relies on extraembryonic tissues to support its growth by exchanging nutrients 
from the maternal body. When only totipotent hybrids can differentiate into 
extraembryonic tissues, they contribute to extraembryonic tissue (in case of ES+4n, 
100% extraembryonic tissues) (Nagy et al., 1990), regardless of the competitive 
growth pressure from 2n cells. As for the embryo, both ES and tetraploid cells can 
differentiate into the three germ layers, where the competitive growth pressure on 
tetraploid cells from the 2n cells counts. Tetraploid cells are only found in the germ 
layers, where they have differentiation bias. The developmental potential of 
pluripotent hybrids ranks between totipotent hybrids and ES/iPS cells, which is 
indicated by less incidence of extraembryonic tissue contribution in chimera assay 
and higher pluripotency score of pluripotent hybrids than parental iPS cells in 
Pluritest (Fig. 4.15B). 
 
5.6 Applications of differentiation propensity of hybrids.  
 
Based on this study, we showed that human hybrids are quite stably maintaining a 
tetraploid phenotype during in vitro and in vivo differentiation. The application of the 
differentiation bias of hybrids is limited by the 4n DNA content, which causes 
concerns about genome instability and tumor generation risk. Clinical application of 
4n hybrids is rather limited, unless for denucleated red blood cells. However one 
study suggested that the enlarged red blood cells derived from hybrids are easy to be 
destroyed when traveling through the capillary, resulting in mass hemorrhage (Snow, 
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1975). Differentiation bias of hybrids could be used as a tool to generate cell types, 
which are notoriously difficult to obtain from ES/iPS cell differentiation, such as 
hepatocytes and lung cells. These differentiated cells represent human diploid 
counterparts, and can be applied in pharmaceutical screening of novel drug candidate.  
 
5.7 Cardiomyocyte differentiation of human iPS cells by using LR704 
and EBIO 
 
For the LR biomaterial project, we found that there was no significant differentiation 
enhancing capacity of the biomaterials compared to tissue culture plate. But we also 
found that the biomaterials have the surface structure of the Teflon foil, due to 
problem in the production process. Since that the surface structure of biomaterials 
could also influence the differentiation efficiency of iPS cells (Markert et al., 2009; 
Purcell et al., 2012), further experiments are needed to address the impact of the 
biomaterial surface on the differentiation capacity of iPS cells. Only till then we can 
conclude whether the LR biomaterial could improve iPS cell differentiation or not.  
 
As for the EBIO experiment, we found that EBIO treatment would impair the 
pluripotency of human iPS cells, but the impact of EBIO on iPS cell differentiation is 
unspecific. Such finding is in consistence with previous studies, which showed that 
upon the activation of SKCas by EBIO, Ras-Mek-Erk signal pathway is activated and 
leads to cell cycle arrest (Kleger et al., 2010; Muller et al., 2012). As an indirect effect 
of cell cycle arrest, differentiation of pluripotent stem cells started. But such 
differentiation is dependent on the stem cells themselves (differentiation propensity), 
rather than EBIO treatment.     
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8 Appendix 
 
8.1 Primer sequences 
 
When no specific reference was indicated, primers were designed by ourselves.  
Table 8.1 Primer sequences for RT-qPCR 
Name (for-rev) Sequences (5’-3’) References 
OCT4 GGGGGTTCTATTTGGGAAGGTA (Tran et al., 
2009)  ACCCACTTCTGCAGCAAGGG 
NANOG CAGAAGGCCTCAGCACCTAC (Zhang et al., 
2009b)  ATTGTTCCAGGTCTGGTTGC 
SOX1 CCTGTGTGTACCCTGGAGTTTCTGT (Yang et al., 
2008)  TGCACGAAGCACCTGCAATAAGATG 
PAX6 TCGAAGGGCCAAATGGAGAAGAGAAG 
 GGTGGGTTGTGGAATTGGTTGGTAGA 
MAP2 TGCAGCTCTGCCTTTAGCAGCTG  
 GATCGTGGAACTCCATCTTCGAGGC 
NF CGAGGAGACCCGACTCAGT  
 CGGGTGGACATCAGATAGGA 
OLIG1 GTCCCTGGAGTTGCGCGCTT  
 CTCGGGGATGGCCTCTCGCT 
GFAP AGGAGGAGGTTCGGGAACTC  
 CGCCATTGCCTCATACTGC 
NESTIN CCTCAAGATGTCCCTCAGCC  
 CCAGCTTGGGGTCCTGAAAG 
T CAGTGGCAGTCTCAGGTTAAGAAGGA (Yang et al., 
2008)  CGCTACTGCAGGTGTGAGCAA 
GSC AACGCGGAGAAGTGGAACAAG (Ahfeldt et al., 
2012)  CTGTCCGAGTCCAAATCGC 
MIXL1 GTACCCCGACATCCACTTGC  
 AGGATTTCCCACTCTGACGC 
EOMES ATCATTACGAAACAGGGCAGGC (Teo et al., 2011) 
 CGGGGTTGGTATTTGTGTAAGG 
CD31 GAGTCCTGCTGACCCTTCTG (Zambidis et al., 
2005)  ATTTTGCACCGTCCAGTCC 
CD34 TGGACCGCGCTTTGCT 
 CCCTGGGTAGGTAACTCTGGG 
CD45 TCAGCCTTGCACACCACAGCTC  
 AAATGACAGCGCTTCCAGAAGGGC 
SCL GGATGCCTTCCCTATGTTCA (Dravid et al., 
2011)  AGGCGGAGGATCTCATTCTT 
RUNX1 CCGAGAACCTCGAAGACATC (Szabo et al., 
2010)  GTCTGACCCTCATGGCTGT 
GATA-1 GGGATCACACTGAGCTTGC 
 ACCCCTGATTCTGGTGTGG 
GATA-2 GGGCTAGGGAACAGATCGACG 
 GCAGCAGTCAGGTGCGGAGG 
PU.1 ACGGATCTATACCAACGCCA 
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 GGGGTGGAAGTCCCAGTAAT 
FLK-1 CCTCTACTCCAGTAAACCTGATTGGG (Kennedy et al., 
2007)  TGTTCCCAGCATTTCACACTATGG 
FLT-3 GGAATGGGTGCTTTGCGATT  
 CAGCACCTTATGTCCGTCCC 
HCN4 ACGCCAAGGCACCTGAAAC (Xiao et al., 
2010)  TGGATGTGGAAGGAGGATGAA 
α-MHC AAGCTCAAGAACGCCTAC (Chen et al., 
1999)  CATTCTTTCCTCCTTCTCC 
WT1 CACAGCACAGGGTACGAGAG (Spandidos et al., 
2010)  CAAGAGTCGGGGCTACTCCA 
OSR1 CGGTGCCTATCCACCCTTC 
 GCAACGCGCTGAAACCATA 
SOX17 AGGAAATCCTCAGACTCCTGGGTT (Yang et al., 
2008)  CCCAAACTGTTCAAGTGGCAGACA 
AFP GCCAAGCTCAGGGTGTAG  
 CAATGACAGCCTCAAGTTGT 
ALB GGTGTGTTTCGTCGAGATG  
 ACTGAGCAAAGGCAATCAAC 
CYP7A1 CGCAAGCAAACACCATTCCA  
 AGGATTGCCTTCCAAGCTGA 
PDX1 CCCATGGATGAAGTCTACC (Sui et al., 
2013b)  GTCCTCCTCCTTTTTCCAC 
CK7 CCAAGGTGGATGCCCTGAAT  
 ACTGCAGCTCTGTCAACTCC 
CDX2 GGCAGCCAAGTGAAAACCAG  
 TTCCTCTCCTTTGCTCTGCG 
NODAL GAGGAGTTTCATCCGACCAA (Ramos-Mejia et 
al., 2010)  GCACTCTGCCATTATCCACA 
WNT3 CTCGCTGGCTACCCAATTTG (Spandidos et al., 
2010)  AGGCTGTCATCTATGGTGGTG 
BMP4 TCACCGTTTTCTCGACTCCG  
 ACGACCATCAGCATTCGGTT 
GAPDH GAAGGTGAAGGTCGGAGTC (Qin et al., 2010) 
 GAAGATGGTGATGGGATTTC 
SK1 ACGCTTACCGACCTAGCCAAG (Chen et al., 
2004)  CTCCAGCTCCTCGTGCTGAG 
SK2 TTACCCTGGAAACAAAACTAGAGACTT 
 TGCCTGATGGTCTGGCTTATG 
SK3 TCCAAGATGCAGAATGTCATGTATG 
 GGTGAGATGCTCCAGCTTCG-3 
SK4 CTCCAAGATGCACATGATCCTGTA 
 GCAGTGCTAAGCAGCTCAGTCA 
 
Table 8.2 Primer sequences for ChIP-qPCR 
Name (for-rev) Sequences (5’-3’) References 
OCT4 TTGCCAGCCATTATCATTCA (Pan et al., 2007) 
 TATAGAGCTGCTGCGGGATT 
NANOG GATTTGTGGGCCTGAAGAAA (Brykczynska et al., 
2010)  GGAAAAAGGGGTTTCCAGAG 
CD45 TCCTGGGTGGTGGGTAAATA (Huff et al., 2010) 
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 AGGCACTGGAAGTCCAACTA 
T GGCACGGCCAAATAAGAATAC  
 CTTGGGTGGTTCAATTCCTG 
GSC TGCGATTTCCTCTGCCTGTA (Teo et al., 2011) 
 ACCAATTCCGAAAGGGGGAA 
MIXL1 GCCCCTCCCAGGCAAATAGT 
 GCAGGAGGGAGGCGTGAAC 
NODAL AGTTCCAGGGACGGGATCTA  
 ACAAGCCTGCTCTGTCTCAG 
 
8.2 Medium composition 
1 Human iPS and ES cells culture medium (250 mL) 
 
KnockOut DMEM 192 mL 
KnockOut Serum Replacement 50 mL 
Non Essential Amino Acid 2.5 mL 
Pen/Strep 2.5 mL 
L-Glutamine 2.5 mL 
β-Mercaptoethanol (50 mM) 500 µL 
bFGF (10,000x) 25 µL 
       
2 MEF culture medium (250 mL) 
 
High glucose DMEM          220 mL 
FCS (Invitrogen; # 41F6504K)               25 mL 
Pen/Strep                    2.5 mL 
L-Glutamine                  2.5 mL 
 
3 HEK293T cells culture medium (250 mL) 
 
High glucose DMEM          220 mL 
FCS (PAA; # A11-151)           25 mL 
Pen/Strep                    2.5 mL 
L-Glutamine                  2.5 mL 
 
4 mTeSR1 medium (100 mL) 
 
mTeSR1 basal medium  80 mL 
5×Supplement medium          20 mL 
 
5 CD34+ HSC culture medium (50 mL) 
 
StemSpan medium              50 mL 
SCF (1,000x)              50 µL 
FLT-3 ligand (500x)                   100 µL 
TPO (1,000x) 50 µL 
Hyper-IL-6 (2,500x)                   20 µL   
Pen/Strep                     500 µL 
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6 Spontaneous differentiation medium (250 mL) 
 
KnockOut DMEM            192 mL 
FCS (Lonza; # 9SB026)                   50 mL 
Non Essential Amino Acid        2.5 mL 
Pen/Strep                     2.5 mL 
L-Glutamine                   2.5 mL 
β-Mercaptoethanol (50 mM)          500 µL 
 
7 Neural differentiation medium  
    Neural diff I (250 mL) 
 
KnockOut DMEM            192 mL 
KnockOut Serum Replacement   50 mL 
Non Essential Amino Acid        2.5 mL 
Pen/Strep                     2.5 mL 
L-Glutamine                   2.5 mL 
β-Mercaptoethanol (50 mM)             500 µL 
             
Neural diff II (200 mL) 
 
DMEM/F12 190 mL 
N2 supplement                 2.5 mL 
B27 supplement                2.5 mL 
Pen/Strep                     2.5 mL 
L-Glutamine                   2.5 mL 
β-Mercaptoethanol (50 mM)            500 µL 
bFGF (10,000x) 20 µL 
EGF (10,000x) 20 µL 
 
Neural diff III (200 mL) 
 
DMEM/F12 190 mL 
N2 supplement                 2.5 mL 
B27 supplement                2.5 mL 
Pen/Strep                     2.5 mL 
L-Glutamine                   2.5 mL 
β-Mercaptoethanol (50 mM)            500 µL 
 
8 Hematopoietic differentiation medium 
Basal medium (250 mL) 
 
StemPro34 244 mL 
Pen/Strep                     2.5 mL 
L-Glutamine                   2.5 mL 
MTG (250x) 1 mL 
L-AA (1,000x) 250 µL 
Transferrin (175x) 1400 µL 
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    Hematopoietic diff I (day 0; 10 mL) 
 
Basal medium 10 mL 
BMP4 (2,500x) 8 µL 
L-AA (1,000x) 10 µL 
 
Hematopoietic diff II (day 1; 10 mL) 
 
Basal medium 10 mL 
BMP4 (2,500x) 8 µL 
L-AA (1,000x) 10 µL 
bFGF (10,000x) 1 µL 
 
Hematopoietic diff III (day 2-4; 10 mL) 
 
Basal medium 10 mL 
BMP4 (2,500x) 8 µL 
L-AA (1,000x) 10 µL 
bFGF (10,000x) 1 µL 
VEGF (10,000x) 1 µL 
SCF (1,000x) 100 µL 
Hyper-IL-6 (2,500x) 4 µL 
IGF-1 (1,600x) 6.25 µL 
 
Hematopoietic diff IV (day 4-6; 10 mL) 
 
Basal medium 10 mL 
bFGF (10,000x) 1 µL 
VEGF (10,000x) 1 µL 
SCF (1,000x) 100 µL 
Hyper-IL-6 (2,500x) 4 µL 
IGF-1 (1,600x) 6.25 µL 
IL-3 (5,000x) 2 µL 
TPO (1,000x) 10 µL 
FLT-3 ligand (2,500x) 4 µL 
 
Hematopoietic diff V (day 6-14; 10 mL) 
 
Basal medium 10 mL 
SCF (1,000x) 100 µL 
IL-3 (5,000x) 2 µL 
TPO (1,000x) 10 µL 
FLT-3 ligand (2,500x) 4 µL 
 
Hematopoietic diff VI (day 14-21; 10 mL) 
 
Basal medium 10 mL 
FLT-3 ligand (250x) 40 µL 
FCS (Gibco; # 531K) 1 mL 
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9 Human mesenchymal stem cells (hMSC) culture medium (250 mL)  
 
Low glucose DMEM          220 mL 
FCS (PAA)           25 mL 
Pen/Strep                     2.5 mL 
L-Glutamine                   2.5 mL 
 
10  Human fibroblast (hFi) culture medium (250 mL)  
 
Low glucose DMEM          220 mL 
FCS (Invitrogen) 25 mL 
Pen/Strep                     2.5 mL 
L-Glutamine                   2.5 mL 
 
11  Cryopreservation medium  
Add 10% DMSO dropwise into ice cold 90% FCS (use the same lot number as in    
culture medium accordingly) 
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